
==== Front
Cell Commun Signal
Cell Commun Signal
Cell Communication and Signaling : CCS
1478-811X
BioMed Central London

1792
10.1186/s12964-024-01792-7
Review
Lipid metabolism reprogramming in endometrial cancer: biological functions and therapeutic implications
Wang Xiangyu
Li Yinuo
Hou Xin
Li Jingfang
http://orcid.org/0000-0003-3414-6158
Ma Xiangyi xyma@tjh.tjmu.edu.cn

grid.33199.31 0000 0004 0368 7223 Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan, Hubei Province 430030 China
10 9 2024
10 9 2024
2024
22 43630 5 2024
15 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Endometrial cancer is one of the major gynecological cancers, with increasing incidence and mortality in the past decades. Emerging preclinical and clinical data have indicated its close association with obesity and dyslipidemia. Metabolism reprogramming has been considered as the hallmark of cancer, to satisfy the extensive need of nutrients and energy for survival and growth. Particularly, lipid metabolism reprogramming has aroused the researchers’ interest in the field of cancer, including tumorigenesis, invasiveness, metastasis, therapeutic resistance and immunity modulation, etc. But the roles of lipid metabolism reprogramming in endometrial cancer have not been fully understood. This review has summarized how lipid metabolism reprogramming induces oncogenesis and progression of endometrial cancer, including the biological functions of aberrant lipid metabolism pathway and altered transcription regulation of lipid metabolism pathway. Besides, we proposed novel therapeutic strategies of targeting lipid metabolism pathway and concentrated on its potential of sensitizing immunotherapy and hormonal therapy, to further optimize the existing treatment modalities of patients with advanced/metastatic endometrial cancer. Moreover, we expect that targeting lipid metabolism plus hormone therapy may block the endometrial malignant transformation and enrich the preventative approaches of endometrial cancer.

Conclusion

Lipid metabolism reprogramming plays an important role in tumor initiation and cancer progression of endometrial cancer. Targeting the core enzymes and transcriptional factors of lipid metabolism pathway alone or in combination with immunotherapy/hormone treatment is expected to decrease the tumor burden and provide promising treatment opportunity for patients with advanced/metastatic endometrial cancer.

Keywords

Endometrial cancer
Lipid metabolism reprogramming
Tumorigenesis
Cancer progression
Targeted therapy
National Key Research & Development Program of China2021YFC2701402 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Endometrial cancer (EC) has become one of the most prevalent gynecological malignancies with 420, 242 newly diagnosed and 97,704 death patients worldwide [1]. Due to lifestyle risk factors like obesity and the lacking of treatment advancement, the incidence and mortality of EC have continued to rise for decades, directly threatening females’ health and survival [2, 3]. Surgery alone or combined with radiation and/or platinum-based chemotherapy as well as hormone therapy can generate good efficacy in most EC patients [4]. However, the 5-year survival rates of patients with stage III/IV tumors remain only 48% and 15% respectively [5]. What’s worse, the median overall survival (OS) of recurrent/metastatic patient is extremely short, ranging from 12 to 15 months [6]. Recently, adjuvant immunotherapy therapy has provided extra treatment opportunity for advanced and metastatic EC patients, but there is ultimately unmet need in the management of almost half of mismatch repair deficient EC and the majority of mismatch repair proficient EC that include copy-number low and copy-number high (P53 mutant) tumors [7, 8]. Thus, it’s necessary to further explicit the biological mechanism of cancer progression, and identify corresponding new therapeutic strategies in EC.

EC is a metabolism disorders-related malignancy [9–12]. Until now, over 50% of EC may be attributed to obesity [3]. Besides, obesity is related to earlier age at diagnosis of EC, suggesting its role in accelerating tumorigenesis [13]. Adipose tissues not only contribute to a proinflammatory microenvironment, but also produce overloaded estrogen, both contributing to the risk of endometrial cancer [4]. Remarkably, dyslipidemia is an independent predictor of endometrial cancer, which promotes the tumorigenesis through obesity [14]. The traditional clinicopathological classification of EC is associated with metabolic risk factors. Bokhman divided EC into two subgroups: Type I tumors are mainly endometrioid, characterized by obesity, hyperglycemia, hyperlipidemia and hyperestrogenism, sensitive to hormone therapy, frequently > 50 years old, with favorable prognosis; Type II tumors are almost serous, insensitive to hormone treatment, usually < 50 years old, with worse clinical outcomes [15]. A large-sample epidemiological research has demonstrated metabolism risk factors like obesity, previously linked to type I EC are also significantly associated with the incidence risk of more aggressive type II EC [16], indicating the metabolic disturbance in tumor progression. In consistent with this, there was a significant increasing trend of the mortality risk in overweighted or obese EC patients [17]. Actually, obesity is the intersection of complex biological processes.

Metabolism reprogramming has been recognized as the hallmark of cancer. Metabolism network was rearranged to induce the transformation of normal cells, and to promote the division of tumor cells in nutrient-depleted conditions [18]. Metabolic adaption also affected the tumor immunity and promote metastasis [19–21]. Tumor cells tended to exploit glycolysis even in aerobic microenvironment, called the “Warburg effect”, which is rewired by tumorigenic mutations in key genes like TP53 and KRAS. Tumoral glycolysis will provide necessary metabolites for lipid synthesis and regulating lipid metabolism pathway [22]. Lipid plays a pivotal role in oncological biology, including serving as constitutional component of cellular bio-membrane, fueling cell growth and mediating signaling transduction, etc [23]. Lipid metabolism reprogramming involving carcinogenesis, invasiveness, metastasis, therapy resistance and immunity of cancer has greatly drawn the researchers’ attention [24–26].

Therefore, we will concentrate on the biologic functions of lipid metabolism reprogramming and aberrant transcriptional regulation of lipid metabolism pathway in endometrial cancer. Importantly, we’ll propose the therapeutic strategies of targeting lipid metabolism pathway and summarize ongoing development of agents under preclinical and clinical assessment, in an attempt to renew the current intervention landscape of EC patients.

The biological functions of lipid metabolism reprogramming in endometrial cancer

Altered lipid uptake promoting tumor proliferation and progression

Abnormal fatty acid uptake

Fatty acid (FA) involves in cellular membrane structure, energy production and signal transduction [27]. Exogeneous FAs serve as an important source of cancer cell growth, dependent on the transportation of several membranous proteins, including CD36, fatty acid transport protein (FATP) and fatty acid binding protein (FABP) [28] (Fig. 1).

It’s reported that CD36 can promote FA uptake via endocytosis mediated by palmitoylation [29]. CD36 was generally upregulated in cancer and could promote tumor growth, metastasis and resistance [30, 31]. CD36 deletion attenuated the liver metastasis of cancer in mice model [32]. Besides, metabolism reprogramming mediated by CD36 induced tumor resistance to anti-HER2 therapy in breast cancer [33]. In pancreatic ductal adenocarcinoma, the expression of CD36 led to gemcitabine-resistant tumor by regulating anti-apoptotic protein [34]. Su et al [35] reported, visceral obesity and metabolic syndrome were directly associated with EC. Adiponectin inhibited the expression of its targeted gene CD36 via downregulating the transcriptional activity of STAT3 signaling, thus reducing peroxisome proliferator-activated receptor (PPAR) activity and suppressing adipocyte differentiation. In contrast, Knapp et al [36] found in grade I, FIGO I endometrioid EC, FA transporters (CD36 and FATP1) were expressed significantly lower than glucose transporter, indicating that CD36 dependent FA uptake may not serve as the main energetic source in early stage, low grade of EC when glucose can be efficiently supplied. But the specific mechanisms of this metabolic switch in EC have not been fully understood. Though some debates seem still existing, the expression and effect of CD36 in glucose-depleted EC will stimulate the research activity.

FABP is able to bind to ligands like long chain FAs. Some literatures reported the dysregulated expression of FABPs facilitated tumor progression [37]. FABP was overexpressed in colon cancer tissue with enhanced lipids accumulation, and promoted the invasiveness and migration by activating AKT pathway and epithelial-mesenchymal transition (EMT) [38]. Also, the upregulation of FABP5 was observed in liver carcinoma, which drove tumor growth via the activation of PI3K/AKT pathway [39]. Moreover, obese breast cancer patients showed significant higher level of circulating FABP, probably because free FABP released from fat tissues stimulated IL-6/STAT3/ALDH signaling pathway, further potentiating cancer cell stemness and invasion [40]. In EC, mass immune blot and immunohistochemistry both indicated significantly increased epidermal FABP (FABP5), in line with spectrometry analysis [41]. Another study demonstrated that compared to normal endometrium and endometrial intraepithelial neoplasia, FABP5 was significantly higher and associated with enhanced immune responsiveness and worse histodifferentiation in EC [42]. However, FABP4 protein and mRNA were reduced in EC. The overexpression of FABP4 exerted inhibitory effect in tumor growth and metastasis by blocking the activation of PI3K/AKT pathway [43], so FABP4 may serve as a tumor suppressor. In short, different subtypes of FABPs have distinct biological effects in EC, which may be the candidate therapeutic target and prognostic biomarker. How to regulate certain isoform of FABPs precisely may be the major challenge in treatment development.

Fig. 1 Lipid uptake and its biological effects in endometrial cancer. FA, fatty acid; FABP, fatty acid binding protein; FATP, fatty acid transportation protein; LDL-C, low-density lipoprotein-cholesterol; LDLR, low-density lipoprotein receptor (By Figdraw)

Abnormal cholesterol uptake

Cholesterol belongs to sterols, as an essential constitutional component of cellular membrane, involved in signaling transduction and biosynthesis [44, 45]. Activated cholesterol uptake was usually observed in proliferative cancer cells. Low-density lipoprotein receptor (LDLR) is a single-transmembrane protein, mediating low-density lipoprotein-cholesterol (LDL-C) into cancer cell and maintaining cholesterol homeostasis [46, 47] (Fig. 1). The expression of LDLR and LDL-C were abnormally increased, and the former was an independent prognostic factor in some malignancies [47]. Previous research demonstrated that hypercholesterolemia contributed to the tumor growth and silencing LDLR reversed the tumor-promoting effect [48]. A Mendelian randomization study showed elevated LDL-C can predict good prognosis in EC, including both endometrioid and non-endometrioid tumors [49]. More importantly, after excluding possible mixed effects of obesity, LDL-C was still significantly related to reduced risk of incidence in EC, especially non-endometrioid diseases [49]. In EC, though the tumor inhibitory effect of LDL-C has been approved, accessible data of LDLR in tumor occurrence and patients’ prognosis are quite limited. So, the definite expression level of LDLR should be determined to better explain the involvement of cholesterol uptake process in EC.

FA and cholesterol uptake can not only provide exogeneous energy for tumor growth and proliferation, but also promote tumor invasiveness and migration by signaling transduction. Though many studies have proved enhanced lipid uptake represents unfavorable outcome in a variety of cancers, some studies have reported its contradictory effects in endometrial cancer. As we know, EC is a malignant tumor with lipid metabolism disorder. More basic and clinical studies are required to clarify whether endometrial cancer has a unique relation to lipid uptake dysregulation.

Aberrant de novo lipogenesis facilitating tumor growth and metastasis

Despite the dependence of exogeneous lipid uptake, endogenous lipid de novo synthesis account for major lipid provision in cancer cell. Lipid biosynthesis mainly contains the synthesis of FA, cholesterol and phospholipid. As the key substrate for FA and cholesterol generation, acetyl-CoA was produced with the catalyzation of ATP-citrate lyase (ACLY) and acetyl-CoA synthetase 2 (ACSS2) [50, 51]. FA production requires acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN), and monounsaturated fatty acid (MUFA) was then produced by stearic acid desaturase (SCD) [28]. Cholesterol was synthesized by 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) and squalene monooxygenase (SM), further esterified into cholesteryl ester by acyl CoA: cholesterol acyltransferase (ACAT). Moreover, phospholipid was synthesized with CTP: phosphocholine cytidylyltransferase catalyzation and phospholipid remodeling was catalyzed by lysophosphatidylcholine acyltransferase. Potentiated lipid synthesis has been considered to promote tumor generation and progression, so comprehensively exploring the influence of disturbed lipid synthesis pathway and related key enzymes expression on tumor development in EC, will be beneficial to predict patients’ prognosis and identify novel hallmarks and therapeutic targets of EC (Fig. 2).

Fig. 2 FAs and cholesterol provision in endometrial cancer. Lipid provision in endometrial cancer includes cellular uptake of exogeneous lipids and intracellular lipid synthesis. Fatty acid uptake is mediated by CD36 and fatty acid transport (FATP) and cholesterol is absorbed by low-density lipoprotein receptor (LDLR) in the form of low-density lipoprotein-cholesterol (LDL-C). Acetyl-CoA is the central metabolic source for de novo lipogenesis, which is mainly derived from citrate produced in tricarboxylic acid (TCA) cycle by ATP-citrate lyase (ACLY) catalyzation, thus closely linking the three major nutrients metabolism pathways to downstream lipid metabolism pathway. Also, acetyl-CoA is partly converted from cytoplasmic acetate with acetyl-CoA synthetase 2 (ACSS2) involvement, especially under the condition of ACLY deletion or metabolic stress. FAs and cholesterol are synthesized with acetyl-CoA, under the control of key enzymes. On one hand, Acetyl-CoA is catalyzed by acetyl-CoA carboxylase (ACC) to produce malonyl CoA. Then, palmitic acid is synthesized by fatty acid synthase (FASN), and subsequently desaturated to monounsaturated fatty acid (MUFA) by stearic acid desaturase 1 (SCD1). MUFAs can be further transformed to PUFAs and/or used to generate glycerophospholipids. On the other hand, HMG-CoA is synthesized with acetyl-CoA and acetoacetyl-CoA, then to produce mevalonate by 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR) catalyzation. Squalene is converted to 2,3-oxidoaualene with SQLE involvement, to produce cholesterol after some steps. In particular, palmitic acid participates in triglyceride (TG) formation and cholesterol is esterified by acyl CoA: cholesterol acyltransferase (ACAT) to CE. Both TG and cholesteryl ester (CE) can be stored in lipid droplets (LDs) (By Figdraw)

Enhanced acetyl-CoA biosynthesis

Acetyl-CoA is at the core of cancer metabolism, which plays a critical role in FA and cholesterol synthesis, and histone acetylation, thus affecting the proliferative and invasive ability of cancer cell [52]. ACLY could drive transformation of citrate into acetyl-CoA, linking three major nutrients catabolic pathways to lipid biosynthesis [53]. ACLY was highly expressed in malignant tumors and can be an independent predictor of cancer recurrence risk [54–56]. Additionally, various mechanisms-induced ACLY upregulation has strongly promote the stemness and/or progression in colon cancer and breast cancer [57–59]. In contrast to this, downregulating ACLY would reduce intracellular lipid synthesis and accumulation by the ubiquitination and degradation of PPARγ, a transcriptional regulator of lipid metabolism pathway [60]. What’s more, acetyl-CoA can epigenetically regulate cancer cell proliferation via histone acetylation. Dai et al [61] found that ACLY mRNA and protein were both hyper-expressed in EC and were obviously correlated to some malignant clinicopathological characteristics and relatively higher BMI. Moreover, following mechanism exploration indicated AKT contributed to tumor cell proliferation via the intracellular nucleus translocation of ACLY, to potentiate histone acetylation and the expression of pyrimidine metabolism genes (like DHODH). Caspase-10 could inhibit acetyl-CoA synthesis by decomposing ACLY, and simultaneously decrease lipid and histone acetylation, effectively suppressing tumor proliferation and metastasis [62]. Thus, ACLY may elicit tumor-stimulatory effects by activating acetyl-CoA production through directly activating downstream lipid metabolism and other mechanisms like epigenetic regulation of DNA biosynthesis in EC.

In recent years, ACSS has been increasingly reported to capture cytoplasmic acetate as a carbon source in cancer, particularly in condition of ACLY genetic deletion or metabolic stress [51, 63, 64]. Among ACSS family members, the oncological biofunction of ACSS2 in cancer has been better described [65]. ACSS2 overexpression was observed in some solid tumor, including breast cancer, liver cancer and prostate cancer, predicting patients’ negative prognosis [66]. ACSS2 can also mediate histone acetylation to augment tumorigenesis. In particular, ACSS2 was highly expressed in obese myeloma patients, and prompted interferon regulator 4 (oncogene) mediated gene transcription by activating acetylation. At the same time, ACSS2 inhibition suppressed tumor growth in obese mouse model [67], indicating that ACSS2 may also play an important role in other obesity-induced tumors, especially EC.

The upregulation of acetyl-CoA synthesis pathway, featured by activated key enzymes like ACLY, is linked to cancer progression of obese malignant tumors and EC, which can fuel tumor growth and metastasis via stimulating acetylation and driving the downstream lipid anabolism pathway. Due to this, key enzymes in acetyl-CoA production will be potential target for EC with unbalanced lipid metabolism.

Potentiated FA biosynthesis

Acetyl-CoA being converted to malonyl CoA by ACC is the first and speed-limiting step in FA synthesis pathway. Then, acetyl-CoA added to malonyl CoA by FASN is to generate long chain saturated FA (or called palmitate), which will be desaturated to monounsaturated fatty acid (MUFA) by stearoyl-CoA desaturase [68].

ACC is divided into ACC1 and ACC2. ACC1 is located in cytoplasm, responsible for FA synthesis while ACC2 is situated at mitochondrial outer-membrane, mainly regulating FA uptake and β-oxidation [69]. ACC can enhance FA synthesis to provide needy energy for tumor cell survival and growth. Adenosine monophosphate activates protein kinase (AMPK) mediated dysregulated ACC1 and ACC2 phosphorylation may potentiate fat accumulation and cell proliferation [70]. Compared to the healthy tissues, the expression levels of ACC1 and ACC2 were increased in EC tissues [71]. Modesitt et al [72] found that in EC tissue of obese women, the inhibitory phosphorylation of ACC by AMPK was reduced with hepatic kinase B1 at a low level, partly explaining the enhanced fat production in these patients. These studies suggest that increased expression/activity of ACC can promote the cancer cell growth through activating FA biosynthesis, which is likely to be associated with obese EC. But direct proofs concerning the influences of ACC overexpression on cancer invasion and metastasis should be provided, and whether ACC can serve as a targetable molecule also requires further exploration in EC.

FASN took control of cancer cell viability and growth by synthesizing FA [73]. In EC, the expression and function of FASN have drawn much attention. It’s reported that the expression level of FASN gradually increased with disease progression as benign endometrium hyperplasia and endometrial dysplasia developed into EC [74]. FASN was expressed in most endometrioid adenocarcinoma and closely associated with the ability of tumor invasiveness and metastasis as well as higher BMI [75], which may independently predict the recurrence risk of EC [76]. Moreover, the overexpression of FASN tends to strengthen the carcinogenicity of EC. FASN expression was upregulated by SNHG25 and RAC3, facilitating the tumoral proliferation, invasiveness and migration [77, 78], while FASN inhibition might induce apoptosis of Ishikawa cell line [79]. In term of this, FASN upregulation is likely to accelerate malignant transformation of endometrium and aggressive biological behaviors, and can be an unfavorable prognostic marker of EC patients.

SCD catalyzed the production of MUFAs, mainly includes palmitoleic acid (16:1) and oleic acid (18:1), which subsequently were used to synthesize more complex lipids, like triglycerides and phospholipids [27, 80]. There are two types of SCD in human, SCD1 and SCD5, and the role of SCD1 is relatively definite [81]. A series of researches demonstrated SCD1 protected cancer cells from ferroptosis threatening, and inhibiting SCD1 effectively suppressed tumor growth and induced cell death [82–84], thus potentially beneficial to prevent cancer recurrence and metastasis. Interestingly, wild-type P53 was able to downregulate the expression of SCD1 by binding to its transcriptional promoter [85], suggesting that P53 mutant tumors may present aberrant lipid metabolism. A study reported that compared to secretory-phase and postmenopausal endometrium, SCD1 was significantly highly expressed in proliferative-phase, hyperplastic and malignant endometrium. More importantly, reduced SCD1 expression showed inhibitory effect on tumor growth in mice [86]. These findings reveal that SCD1 overexpression may contribute to maintaining cancer cell viability and promoting cancer progression, and SCD1 inhibition has significant killing effect on cancer cell, shedding light on treatment strategy establishment for EC.

Abnormally activated FA biosynthesis lays a solid foundation of cancer cell growth in EC, which can be effectively reversed by inhibiting FA production. The upregulation of FA de novo synthesis can be an unfavorable prognostic marker of EC patients, characterized by increased FASN and SCD expression, suggesting that enhanced FA synthesis may be involved in EC progression.

Increased cholesterol biosynthesis

Cholesterol biosynthesis is manipulated by HMGCR and SM, which are responsible for converting HMG-CoA to MVA (namely mevaleric acid pathway) and squalene to 2,3-epoxy squalene, respectively [87]. Recently, increased cholesterol synthesis has been considered to accelerate oncogenesis and tumor progression.

HMGCR was reported to be correlated with the risk of various cancers, and be involved in tumor growth and metastasis regulation [88–91]. FASN silencing could upregulate the expression of HMGCR by activating sterol regulatory element binding protein 2 (SREBP2), to enhance cholesterol production and cancer cell growth [92]. Besides, genetic alternation-induced HMGCR inactivation indicated reduced risk of ovarian cancer and breast cancer [93, 94], which lays a theoretic basis for the reuse of statins in anti-tumor treatment. Notably, analysis of transcriptomic sequencing data based on ovarian cancer, EC and cervix cancer showed that cholesterol related genes may contribute to tumoral resistance through cholesterol homeostasis and FA metabolism pathway [95]. These preliminary findings inspire researchers to explore the practicability of targeting HMGCR and predict tumoral response to anti-tumor therapy based on HMGCR expression status in EC.

SM, also called squalene cyclooxygenase (SQLE), was reported to promote tumor growth and progression in cancer [96–100]. Ma et al [101] has recently reported that significantly overexpressed SQLE was observed in EC patients by TCGA data analysis and IHC validation. Besides, SQLE drove the proliferation and metastasis of EC cell lines (Ishikawa and KLE) via upregulating PI3K/AKT signaling in vitro, which added the proofs of abnormal cholesterol metabolism to existing literatures in EC. Coates et al [102] initially revealed the upregulated truncation of SQLE could contribute to lipogenesis in EC. Hence, SQLE is commonly overexpressed to endogenously provide cholesterol for cancer cell and will become another therapeutic target in EC.

Acyl-CoA: cholesterol acyltransferase (ACAT), can transform free cholesterol into cholesterol ester, thus alleviating the cellular toxicity by overloaded free cholesterol [103]. There are two subtypes of ACAT in mammal animal as reported: ACAT1 (widely distributed) and ACAT2 (preferred in intestine and liver) [104]. ACAT was significantly correlated with recurrence-free survival in cancer [105]. For EC, a study demonstrated the activity of ACAT in malignant endometrium was significantly greater than healthy secretory endometrium [106]. A study based on bioinformation analysis demonstrated that compared to normal tissue, seven cholesterol homeostasis related genes (like ACAT2) were significantly upregulated, and the constructed cholesterol homeostasis related genes signature could serve as a predictive tool of poor survival outcome for EC patients [107]. In all, increased expression of ACAT is able to facilitate the prognosis prediction of cancers, including EC, and reducing the expression of ACAT inhibits tumor growth. So, ACAT-mediated cholesterol esterification may play a critical role in tumor cell survival, which is worth further investigation in EC.

Previous researches have showed that the upregulated cholesterol biosynthesis pathway can boost malignant tumor survival and growth in EC. In addition, the key enzyme of cholesterol esterification, ACAT, is highly expressed in EC tissues, indicating the cholesterol metabolism related tumor protective mechanisms to some degree.

Abnormal lipid catabolism exerting diverse roles

Fat acid oxidation

Fat acid oxidation (FAO) is mainly conducted by mitochondrial β-oxidation and is able to drive the tumoral proliferation, metastasis and resistance, etc [108]. The initial program of FAO is that FAs are activated to acyl-CoA by long-chain acyl-CoA synthetase (ACSL). In the following, lipoylcarnitine is synthesized with acyl-CoA, catalyzed by carnitine palmitoyltransferase1 (CPT1) in outer mitochondrial membrane, and subsequently entry into the mitochondria, which is the speed-decisive step in FAO process [108] (Fig. 3). Quan et al [109] clarified that ACSL3 was upregulated by TGFβ1 via SREBP1 and stimulated ATP and NADPH generation by triggering FAO pathway, thus facilitating EMT and tumor spread. Tang et al [110] reported that high CPT1 expression greatly enhanced tumor proliferation, non-anchored growth and lesions formation. In EC, the abnormal expression or genetic changes of ACSL is linked to malignant biological characteristics and patients’ prognosis. Zhou et al. [111] reported that ACSL1 overexpression upregulated FAO process and energy provision by activating AMPK/CPT1C/ATP pathway, thus promoting cancer cell to proliferate and migrate, which was also predominantly associated with malignant advancement of EC. Yu et al [112] using UALCAN database found that compared to normal tissue, ACSL4 protein was relatively higher in EC lesions, consistent with the results from TIMER and GEPIA databases. According to HPA database, ACSL4 protein presented strongly positive in EC tissue. At the same time, ACSL4 genetic mutation suggested longer progression-free survival period of patients with EC while copy number amplification of ACSL4 predicted much worse outcome of the patients [112]. In short, FAO pathway upregulation may serve as a useful predictor for unfavorable prognosis of EC, and key enzymes like ACSL and CPT1 represent promising treatment targets in EC.

Fig. 3 The key enzymes and products of FAO in endometrial cancer. ACSL, long-chain acyl-CoA synthetase; CPT1, carnitine palmitoyltransferase1; FAO, fatty acid oxidation; TCA, tricarboxylic acid (By Figdraw)

Cholesterol efflux

Cholesterol homeostasis is necessary for maintaining cancer cell survival and growth. Of note, over-accumulation of cholesterol is harmful to cancer cells. Cholesterol efflux has become an effective strategy to avoid lipid toxicity in cancer cell, because cholesterol is difficult to absolutely break down in human peripheral tissues. Four conventional cholesterol efflux pathways include: passive diffusion, SR-B1 promoting diffusion, ATP binding cassette subfamily A member 1 (ABCA1) mediating efflux to pre-β1 high-density lipoprotein (HDL) and ATP binding cassette subfamily G member 1 (ABCG1) mediating efflux to mature HDL [113, 114]. In EC, Antmen et al [115] discovered that ABCA1 was significantly higher in tumor tissues that control group. Interestingly, as the histodifferentiation of endometrial adenocarcinoma went worse (from grade 1 to grade 3), ABCA1 expression level presented a relatively decreasing trend, suggesting the tumor promoting role of increased cholesterol in cancer cell by reduced ABCA1 in endometrioid cancer. Besides, ABCA1 activation by NNMT1 can enhance cholesterol efflux and cellular membrane fluidity, thus stimulating EMT process of EC [116]. Additionally, higher HDL-cholesterol apparently increased the risk of non-endometrioid tumor [49], indicating cholesterol efflux may accelerate the development of EC with more malignant histological subtypes. Until now, ABCA1-mediated cholesterol efflux has been considered to be an adaptive approach of cancer cell to maintain cholesterol homeostasis and survival in EC. But whether some molecules of other cholesterol efflux ways will be involved in the intra-and extra-cellular cholesterol regulation and the underlying mechanisms should be further elucidated in EC.

Altered transcriptional regulation of lipid metabolism

SREBP

SREBP is a kind of transcription factors. Nuclear SREBP will activate lipid uptake and synthesis-related genes of lipid metabolism pathway by sterol regulating element (SRE). There have been three well-known SREBPs: SREBP1a, mainly regulating reactive genes in FA and cholesterol de novo synthesis processes; SREBP1c, affecting FA synthesis related genes and involving lipocyte differentiation, whose downstream enzymes includes ACC, FASN and SCD1;SREBP2, responsible for regulating cholesterol uptake and synthesis by influencing LDLR and HMGCR [24, 117–119].

SREBP1 and SREBP2 as well as downstream enzymes regulated by them were involved in lipid metabolism reprogramming and disease progression in cancer [120, 121]. Shafiee et al [122] reported SREBP1 was significantly elevated in EC tissues than in health tissues, positively associated with serum triglycerides. Li et al [123] found that compared to normal tissues, SREBP1 was significantly upregulated in poorly differentiated EC tissues and mainly located in nucleus, indicating its tumor-promoting effect in EC. Besides, SREBP1 target molecules (like FASN, SCD and ACLY) were overexpressed in AN3CA EC cell line, and the expression of these key enzymes were accordingly reduced by SREBP1 downregulation by shRNA. Subsequent experiments demonstrated SREBP1 knockdown hindered proliferation and growth, and showed tumor killing effects in EC. Qiu et al [124] analyzed the SREBP1 gene in EC lesions (n = 30) and benign specimens (n = 6) based on high throughput sequencing, with single nucleotides polymorphisms (rs2297508) as the target marker. Consequently, single nucleotides polymorphisms (rs2297508) and C alleles was detected in 40% of EC, significantly more frequent than control group and linked to the histological differentiation and involvement of myometrium. The above studies demonstrate that the upregulation and some specific genetic variations of SREBP1 define malignant characteristics of EC, so SREBP1 inhibition may facilitate tumor regression by reducing lipid provision (endogenous synthesis and exogeneous uptake).

Liver X receptor

Liver X receptor (LXR), a nuclear receptor super family member, includes LXRα and LXRβ. LXR can act as a transcriptional regulator of SREBP1c and maintain cholesterol homeostasis [118, 125]. For one thing, LXR is combined and activated by a variety of oxidized sterols, then binding to retinol X receptor to form a heterodimer, specifically enhancing SREBP1c transcription to increase FA synthesis [126, 127], further promoting free cholesterol esterification to reduce extra toxicity from free cholesterol. For another, LXR activation could positively regulate ABCA1 expression to potentiate cholesterol efflux, and ubiquitously suppress LDLR by inducing Idol expression at transcription level, thus reducing cholesterol uptake [125, 128]. Otherwise, LXR activation could also induce the transcription of phospholipid remodeling enzyme (LPCAT3), preferentially driving the incorporation of unsaturated FAs into phospholipids to maintain the membrane homeostasis [129]. Fang et al [130] found by immunohistochemistry analysis that compared to normal and endometrial polyp tissues, LXRα was apparently overexpressed in endometrioid EC lesion and mainly distributed in cytoplasm of Ishikawa cell line. In addition, LXR impaired endometrial adenocarcinoma cell viability by inhibiting cyclin D1 and cyclin E expression. 27- hydroxycholesterol, a product of cholesterol metabolism, could be an endogenous activator of LXR and estrogen receptor [131]. Gibson et al [132] reported 27- hydroxycholesterol selectively activated estrogen receptor signaling to stimulate proliferation of Ishikawa and RL95-2 cells, which was reversed by external activation of LXR. Given that LXR has multiple effects on lipid metabolism regulation, systematic knowledge of LXR and of its upstream/downstream regulation mechanisms in EC should be established, to guide the exploration of effective therapeutic agents targeting LXR.

PPAR

PPAR belongs to nuclear hormone receptor super family and regulates lipid metabolism as a ligand-induced transcription factor [133, 134]. There are three subtypes of PPAR: PPARα, regulating FA transportation, esterification and oxidation processes; PPARβ/δ, mainly involving in FA oxidation; PPARγ, enhancing energy accumulation by affecting FA transportation, fat production and FA biosynthesis [133]. PPAR was reported to participate in diverse biological processes, such as tumor proliferation, vessels formation, invasion/metastasis, self-renewing, metabolism and immunology, etc [135].

Until now, related studies have demonstrated PPAR activation may exert anti-tumor effects in EC. A series of data supported PPARα and PPAR β/δ were expressed more strongly in EC tissues than non-malignant tissues, while the expression level of PPARγ was relatively decreased in EC [136–140]. But another study has reported that the expression of PPARα was lower in EC tissues than normal tissues recently [141]. Despite the distinct expression profiles of PPARα and PPARγ, their activation both inhibited tumor cell proliferation and angiogenesis in EC [140, 141]. Moreover, PPARγ activation attenuated proliferation, migration and invasion abilities of EC cells (especially EEC-1) and downregulated the estrogen receptor expression in estrogen receptor-positive EEC-1 cell line [138]. Additionally, activated PPARβ/δ exerted anti-tumor effect by inhibiting AKT/GSK3β/β-catenin pathway [142]. Previous studies have revealed both PPAR activation and inhibition have shown anti-tumor potential, which broaden our perspectives of complicated lipid metabolism transcriptional regulation and will arouse researchers’ interest to further investigate the underlying mechanisms and evaluate the effectiveness of targeting PPARs in EC. The key point is how to balance the status of PPARs to hinder the tumor progression of EC.

Targeting lipid metabolism as monotherapy in endometrial cancer

Growing studies have shown lipid metabolism alternations are associated with the occurrence, invasion, metastasis and recurrence of various cancers (including EC). Therefore, targeting key enzymes and related transcription factor of lipid metabolism pathway could be potential therapeutic strategy to inhibit cancer progression in EC (Fig. 4). Until now, a series of drugs targeting lipid metabolism pathway have been used as monotherapy to evaluate preclinical and clinical anti-tumor activity in EC.Fig. 4 Potential molecular targets and relevant agents of lipid metabolism in endometrial cancer. sterol regulatory element binding protein (SREBP) activates lipid uptake and synthesis-related genes of lipid metabolism pathway by sterol regulating element (SRE). SREBP2 is responsible for regulating cholesterol uptake and synthesis by influencing low-density lipoprotein receptor (LDLR) and 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR). Activated liver X receptor (LXR) binds to retinol X receptor (RXR) to form a heterodimer, specifically enhancing SREBP1c transcription to increase fatty acid (FA) synthesis and maintaining cholesterol homeostasis. LXR activation can also positively regulate ATP binding cassette subfamily A member 1 (ABCA1) expression to potentiate cholesterol efflux, and ubiquitously suppress LDLR. Peroxisome proliferation activates receptor (PPAR) regulates lipid metabolism by influencing FA uptake, FA synthesis and fatty acid oxidation (FAO). Notably, fatty acid synthase (FASN), stearic acid desaturase (SCD1), 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGCR), squalene cyclooxygenase (SQLE), SREBP and PPAR are potential therapeutic targets of aberrant lipid metabolism in endometrial cancer (By Figdraw)

FASN inhibitor

FASN is speed-limiting in FA synthesis pathway, and its overexpression will activate FA synthesis process, promoting EC invasion and migration. Due to this, inhibiting FA metabolism is a charming tumor interventional strategy and FASN inhibitors are increasingly developed in anti-tumor treatment. Orlistat, a robust FASN inhibitor, has been proved to reprogram oncological biology [143]. Wysham et al [144] assessed the anti-tumor activity of orlistat in ECC-1 and KLE cell lines and found orlistat at 500µM level could make the proliferative activity of cancer cells decrease by 61% and 57%, respectively. What’s more, Western blot analysis indicated orlistat reduced the expression of core enzymes (like FASN, ACC and CPT1A) in lipid metabolism pathway, upregulated phosphorylated AMPK expression and downregulated phosphorylated AKT expression. Mycotoxin cerulenin is a covalently bound inactivator of FASN and C75 is a novel small molecular inhibitor of FASN. Menendez et al [79] reported that cerulenin and C75 treatment remarkably abrogated tamoxifen-activated estrogen response element-relied transcription and estradiol-induced upregulation of oncogenes (like ERα and HER2), thus probably preventing malignant transformation of endometrium and inhibiting the viability and proliferation of EC cells. Excitingly, a clinical trial first evaluated safety and pharmacology of FASN inhibitor TVB-2640 (denifanstat) alone (n = 76) or combined with paclitaxel (n = 60) in advanced solid tumors (EC included). TVB-2460 monotherapy was able to accomplish a disease control rate of 42%. TVB-2640 combined with paclitaxel would reach 70% disease control rate and 12% partial response rate, with manageable drug safety [145]. Preclinical studies reveal that FASN inhibitors have initial anti-tumor activity and more clinical trials are in need to evaluate the feasibility of applying FASN inhibitors in EC patients with lipid metabolic disorder.

SCD1 inhibitor

SCD1 is responsible for the generation of unsaturated FAs, involving cancer ferroptosis resistance and metastasis, which has been considered as a potent target for cancer therapy [84, 146]. SCD1 knockdown or inhibited by A939572 damaged the tumor cell growth, promoted apoptotic program in vitro and abrogated the capability of metastatic lesions formation of EC AN3CA cell line in vivo [86].

HMGCR inhibitor

HMGCR, key enzyme of cholesterol biosynthesis, is highly expressed in cancer, to satisfy the extra need of cholesterol for tumor growth. Statins are able to regulate lipids level by inhibiting HMGCR and have been widely used in cardiovascular diseases management. More importantly, statins were reported to reduce the risk of tumorigenesis and improve prognosis benefits in cancers [147]. Hence, the repurposing of statins in anti-tumor field has become a hot topic [148]. Simvastatin is first-generation HMGCR inhibitor. Schointuch et al [149] found simvastatin treatment significantly inhibited the proliferation, invasion and migration ability of ECC-1 and Ishikawa cell lines as well as primary cancer cells derived from EC patients. Zhou et al. revealed [150] that simvastatin could block cancer cell proliferation and invasion by downregulating the RAS/MAPK signaling and induce reactive oxygen species and ferroptosis. Moreover, simvastatin plus metformin showed synergistic anti-tumor effects in RL95-2, HEC-1B and Ishikawa EC cell lines, possibly mediated by mTOR signaling and apoptosis [151]. Fluvastatin is the first completely synthesized second-generation HMGCR inhibitor. Cai et al [152]reported that fluvastatin impaired aggressive characteristics of EC cells and induced cell death. It should be emphasized that a clinical trial (NCT0276736) has accomplished the preliminary assessment of anti-proliferation activity of atorvastatin in EC.

SQLE inhibitor

SQLE is another rate-limiting enzyme for cholesterol biosynthesis. SQLE inhibitor like terbinafine and NB-598 effectively promoted the apoptosis and inactivated MAPK and PI3K/AKT pathway [153]. SQLE knockdown by shRNA or chemical inhibition by terbinafine could repress the P53-deficiency induced tumorigenesis and growth [154]. Du et al [155] proposed that SQLE was a promising therapeutic target in P53 mutant colorectal cancer, enlightening the novel treatment strategy of P53 mutant tumors. Silencing or pharmacological inhibition by terbinafine obviously reduced tumor growth of EC, indicating the therapeutic potential of SQLE inhibitor [101].

SREBP inhibitor

SREBP transcriptionally regulates lipid biosynthesis in various malignant tumors, and inhibiting SREBP may become a potent anti-tumor strategy. Fatostatin is an inhibitory agent of SREBP. Gao et al [156] revealed that fatostatin treatment could suppress the viability, clone formation and aggressiveness of EC cells, and exerted tumor killing effects by initiating cancer cell apoptosis, where SREBP1 and its downstream lipid synthases were noticeably downregulated with decreased intracellular free FAs and cholesterol. Similarly, Yao et al [157] also discovered fatostatin resulted in tumor regression by targeting lipid metabolism by in vitro and in vivo experiments. Research results in xenograft model have demonstrated fatostatin suppressed tumor growth and expansion, simultaneously disturbing tumor cell cycle and promoting cell death in EC. BF175, a new SREBP inhibitor, has shown lipid-lowering effects. Wang et al [158] initially reported BF175 dramatically hindered cell proliferation and migration of AN3CA cells by triggering autophagy and mitochondrial pathway associated apoptosis. In addition, BF175 also effectively downregulated SREBP and its downstream genes, to reduce FAs and cholesterol production. Furthermore, novel anti-tumor drug silibinin was considered to block lipid synthesis by inactivating STAT3 and SREBP signaling, causing damaged cell proliferation and activated apoptosis in EC [159]. Though in vitro and in vivo experiments suggest that SREBP inhibitor contribute to tumor inhibition, its safety and activity should be determined in more basic and clinical studies.

PPAR modulator

PPAR acted as a transcriptional regulator of lipid metabolism, involved in a variety of oncological biological processes, including lipids transportation, synthesis and catabolism, etc. PPAR signaling also plays an important role in tumor immune response. Interestingly, PPARs have shown bilateral functions in cancer development. PPAR modulators (agonist and antagonist) were both reported to have great cancer management potential [133]. Fibrates can serve as PPARα agonist. Fenofibrate effectively improved the sensitivity of breast cancer, prostate cancer and non-small cell lung cancer to chemotherapy or targeted therapy [160–162]. In EC, fenofibrate was able to suppress cancer cell expansion and stimulate apoptosis probably by inhibiting PPAR regulating FA metabolism pathway [163, 164]. Irbesartan, as a PPAR agonist, can also inhibit the proliferation of EC HEC-1 A and Ishikawa cell lines, by simultaneously inactivating the SREBP1 and activating the tumor suppressing genes [141]. Classical PPARγ agonists are known as isthiazolidinediones, containing troglitazone, rosiglitazone, pioglitazone, ciglitazone and inolitazone/efatutazone, etc. Kumari et al [165] first investigated the anti-tumor efficacy of pioglitazone in EC mouse model (n = 50) and found that compared to standard paclitaxel treatment, pioglitazone inhibited tumor lesions formation and growth in a dose dependent manner. Furthermore, GW0742 and GW501516 were two highly selective PPARβ/δ activators, able to activate PPAR signaling pathway, leading to the inhibition of tumoral proliferative capacity and apoptosis in EC [142]. Thus, the anti-tumor effect on part of PPAR modulators (mainly agonists), has been preliminarily determined in EC, but the anti-tumor efficacy of some PPAR inhibitors should be highlighted in future studies.

Collectively, targeting lipid metabolism pathway and related transcriptional regulation factors is a promising anti-tumor therapy in malignant tumors, and relevant agents has entered clinical trials (Table 1). The expansion of clinical trials in pan-cancer has encouraged the basic and clinical exploration of lipid metabolism-targeted therapies in EC (Table 2). Therefore, we could reasonably predict that targeting lipid metabolism will become spotlight of EC research in the approaching future, to prevent the development of EC and to improve the prognosis of EC patients, particularly in women with obesity or lipid metabolism disturbance.

Table 1 Clinical trials of targeting lipid metabolism in malignancies (ClinicalTrials.gov)

Drug	Target	Effect	Malignancy	Phase	Patient	NCT Number	
TVB-2640 (Denifanstat)	FASN	Inhibitor	KRAS-mutant non-small cell lung carcinoma	Phase 2	34	NCT03808558	
TVB-2640 (Denifanstat)	FASN	Inhibitor	HER2-positive metastatic breast cancer	Phase 2	19	NCT03179904	
TVB-2640 (Denifanstat)	FASN	Inhibitor	Recurrent high-grade astrocytoma	Phase 2	25	NCT03032484	
TVB-2640 (Denifanstat)	FASN	Inhibitor	Metastatic castration-resistant prostate cancer	Phase 1	30	NCT05743621	
TVB-2640 (Denifanstat)	FASN	Inhibitor	Colon cancer	Phase 1	48	NCT02980029	
TVB-2640 (Denifanstat)	FASN	Inhibitor	Solid malignant tumor	Phase 1	180	NCT02223247	
Berberine	SCD1	Inhibitor	EGFR-mutant lung adenocarcinoma	Phase 2	50	NCT03486496	
Atorvastatin	HMGCR	Inhibitor	Hepatocellular carcinoma	Phase 4	240	NCT03024684	
Atorvastatin	HMGCR	Inhibitor	Metastatic/recurrent prostate cancer	Phase 3	400	NCT04026230	
Atorvastatin	HMGCR	Inhibitor	Breast cancer	Phase 3	314	NCT03971019	
Atorvastatin	HMGCR	Inhibitor	HER2 negative breast cancer	Phase 2 Phase 3	60	NCT05103644	
Atorvastatin	HMGCR	Inhibitor	High-risk stage IIA melanoma	Phase 2	150	NCT06157099	
Atorvastatin	HMGCR	Inhibitor	Locally advanced prostate cancer	Phase 2	364	NCT01759836	
Atorvastatin	HMGCR	Inhibitor	p53-mutant and wild-type malignancies	Phase 1	50	NCT03560882	
Simvastatin	HMGCR	Inhibitor	Breast cancer	Phase 3	314	NCT03971019	
Rosuvastatin	HMGCR	Inhibitor	Metastatic prostate cancer	Phase 4	70	NCT04776889	
Rosuvastatin	HMGCR	Inhibitor	Rectal cancer	Phase 2	45	NCT02569645	
Rosuvastatin	HMGCR	Inhibitor	Solid tumor	Phase 1	19	NCT04428086	
Rosuvastatin	HMGCR	Inhibitor	Squamous cell carcinoma and non-small cell lung cancer	Phase 1	24	NCT00966472	
Silibinin	SREBP	Inhibitor	EGFR-mutant lung adenocarcinoma	Phase 2	42	NCT02146118	
Silibinin	SREBP	Inhibitor	Non-small cell lung cancer and breast cancer	Not applicable	70	NCT05689619	
TPST-1120	PPAR	Antagonist	Advanced liver cancer	Phase 1 Phase 2	400	NCT04524871	
TPST-1120	PPAR	Antagonist	Advanced cancer	Phase 1	138	NCT03829436	
Inolitazone (Efatutazone)	PPAR	Agonist	Myxoid liposarcoma	Phase 2	15	NCT02249949	
Inolitazone (Efatutazone)	PPAR	Agonist	Advanced anaplastic thyroid cancer	Phase 2	19	NCT02152137	
Inolitazone (Efatutazone)	PPAR	Agonist	Colorectal cancer	Phase 2	84	NCT00986440	
Pioglitazone	PPAR	Agonist	Lung cancer	Phase 2	92	NCT00780234	
Pioglitazone	PPAR	Agonist	Pancreatic cancer	Phase 2	14	NCT01838317	
Rosiglitazone	PPAR	Agonist	Liposarcoma	Phase 2	32	NCT00004180	

Table 2 Preclinical and clinical studies of targeting lipid metabolism in endometrial cancer

Drug	Target	Effect	Objective	Study type	Reference	
TVB 2640 (Denifanstat)	FASN	Inhibitor	Refractory metastatic or advanced solid malignant tumors (including endometrial cancer)	Clinical (Phase 1)	[145]	
Orlistat	FASN	Inhibitor	Endometrial cancer ECC-1 and KLE cell lines	Basic	[144]	
Mycotoxin cerulenin	FASN	Inhibitor	Endometrial cancer Ishikawa cell line	Basic	[79]	
C75	FASN	Inhibitor	Endometrial cancer Ishikawa cell line	Basic	[79]	
A939572	SCD1	Inhibitor	Endometrial cancer EEC-1, HEC-1 A, RL95-2, AN3CA, KLE, SPEC-2 cell lines	Basic	[86]	
Atorvastatin	HMGCR	Inhibitor	Endometrial cancer patients	Clinical (Phase 2)	NCT05675787	
Atorvastatin	HMGCR	Inhibitor	Endometrial cancer patients	Clinical (Phase 1)	NCT02767362	
Rosuvastatin	HMGCR	Inhibitor	Endometrial cancer patients	Clinical (Phase 2)	NCT04491643	
Simvastatin	HMGCR	Inhibitor	Endometrial cancer ECC-1 and Ishikawa cell lines, as well as primary cancer cells from patients	Basic	[149]	
Simvastatin	HMGCR	Inhibitor	Endometrial cancer Ishikawa cell line	Basic	[150]	
Simvastatin	HMGCR	Inhibitor	Endometrial cancer RL95-2, HEC-1 B and Ishikawa cell lines	Basic	[151]	
Fluvastatin	HMGCR	Inhibitor	Endometrial cancer RL95-2 and KLE cell lines	Basic	[152]	
Terbinafine	SQLE	Inhibitor	Endometrial cancer Ishikawa and KLE cell lines, and  nude mice	Basic	[101]	
Fatostatin	SREBP	Inhibitor	Endometrial cancer Ishikawa and HEC-1 A cell lines	Basic	[156]	
Fatostatin	SREBP	Inhibitor	Endometrial cancer xenograft model	Basic	[157]	
BF175	SREBP	Inhibitor	Endometrial cancer AN3CA cell lines	Basic	[158]	
Silibinin	SREBP	Inhibitor	Endometrial cancer Ishikawa and RL95-2 cell lines	Basic	[159]	
Fenofibrate	PPAR	Agonist	Endometrial cancer Ishikawa cell line	Basic	[164]	
Irbesartan	PPAR	Agonist	Endometrial cancer HEC-1 A and Ishikawa cell lines	Basic	[141]	
Pioglitazone	PPAR	Agonist	Endometrial cancer mice model	Basic	[165]	
GW0742	PPAR	Agonist	Endometrial cancer Ishikawa, RL95-2 and Sawano cell lines	Basic	[142]	
GW501516	PPAR	Agonist	Endometrial cancer Ishikawa, RL95-2 and Sawano cell lines	Basic	[142]	

Targeting lipid metabolism in combinational therapy of endometrial cancer

Given that solely targeting lipid metabolism pathway demonstrates promising therapeutic potential in EC management, its combination with immunotherapy is increasingly in development. Among lipid metabolism pathway targeted drugs, PPAR modulators have been mostly reported to improve the anti-tumor efficacy of immunotherapy. Interestingly, in diet-induced obese female mice, GW9662 combined with anti-PD-L1 immunotherapy showed anti-tumor activity. A clinical study (NCT04114136) has been designed to explore whether PPARγ antagonist (rosiglitazone) can remodel tumor immune microenvironment to potentiate tumor killing effects of T cells and improve the tumoral sensitivity to anti-PD-1 treatment in solid tumors. Also, the safety and tolerance of rosiglitazone combined with nivolumab/pembrolizumab are closely monitored. In addition, NCT03829436 is a phase 1 clinical trial, aiming to determine the drug toxicity and maximum tolerant dosage of PPARα antagonist (TSPT-1120) alone or combined with nivolumab (PD-L1 inhibitor) in advanced solid tumor. NCT04524871 is designed to evaluate clinical efficacy of different combinations of immunotherapy in advanced liver cancer, including atezolizumab (PD-1 inhibitor), bevacizumab and TSPT-1120.

Simultaneously, progesterone is applied in systematic management of EC, but tumor resistance to progesterone has severely decreased its clinical efficacy. Inspiringly, the strategy of targeting lipid metabolism pathway combined with progesterone is undergoing preliminary clinical investigation. A phase 2 clinical study (NCT05675787) is recruiting patients, in order to assess the efficacy of MPA plus atorvastatin in young patients with early-stage EC. Another phase 2 clinical trial (NCT04491643) is to investigate the anti-tumor effects of MA in combination with rosuvastatin in young, stage I EC patients. Similarly, Progesterone regimen and several statins are applied in patients with early-stage EC (NCT06102863).

Therefore, these active clinical researches strongly support that targeting lipid metabolism pathway sensitizing immunotherapy has become a potentially promising anti-tumor strategy in advanced solid tumor, and particularly in EC (Table 3). On one hand, anti-PD-1/PD-L1 immunotherapy has made breakthrough in EC chemical intervention, so it’s necessary to further investigate whether lipid metabolism targeted therapy added to immunotherapy can rescue more patients with EC. On the other hand, the therapeutic efficacy of lipid metabolism pathway targeted drugs (especially statins) plus progesterone is required to elucidate its potential as a conservative treatment for women at high risk of EC (such as obesity, metabolic syndrome and dyslipidemia) and to improve the survival of EC patients.

Table 3 Clinical trials of targeting lipid metabolism pathway in combinational therapy of cancers (ClinicalTrials.gov)

Regimen	Drug	Malignancy	Patient	Phase	NCT Number	
Hormone therapy +

HMGCR inhibitor

	Progesterone + Atorvastatin/

Rosuvastatin/

Pivastatin

	Endometrial carcinoma stage I	38	Phase 2	NCT06102863	
Hormone therapy +

HMGCR inhibitor

	Medroxyprogesterone acetate + Atorvastatin	Endometrial carcinoma stage I	82	Phase 2	NCT05675787	
Hormone therapy +

HMGCR inhibitor

	Megestrol Acetate + Rosuvastatin	Endometrial carcinoma stage I	48	Phase 2	NCT04491643	
PD-1 inhibitor +

PPAR agonist

	Nivolumab/

Pembrolizumab + Rosiglitazone

	Solid tumor malignancies	72	Phase 2	NCT04114136	
PD-1 inhibitor +

PPAR antagonist

	Nivolumab +  TPST-1120	Advanced cancers	38	Phase 1	NCT03829436	
PD-L1 inhibitor +

PPAR antagonist

	Atezolizumab +  TPST-1120	Advanced liver cancers	400	Phase 1/2	NCT04524871	

Conclusion

The increasing incidence and morality of EC can be largely attributed to metabolic disorders like obesity and hyperlipidemia. Lipid metabolism reprogramming is initiated by genetic alternations especially P53 mutation, which is remarkably associated with the worst prognosis of EC patients. In general, the activated endogenous lipogenesis (FA and cholesterol biosynthesis) and FAO process play a pivotal role in inducing tumor initiation, proliferation, invasion, metastasis and stemness, as well as tumor microenvironment remodeling and therapeutic resistance in EC. Besides, various signaling pathways are rewired by aberrant lipid metabolism to elicit tumor-promoting functions (Fig. 5). The alternations of some key enzymes (especially FASN, SCD1, HMGCR and SQLE) and transcriptional factors (SREBP, LXR and PPAR) define the lipid metabolism dysregulation in tumorigenesis and progression of EC, which has become the excellent candidate targets for treatment exploration. To date, drugs targeting lipid metabolism related pathway have shown preliminary anti-tumor activity in EC. Importantly, sensitizing hormonal therapy by targeting lipid metabolism pathway is undergoing assessment in early phase clinical trials in EC.Fig. 5 The landscape of aberrant lipid metabolism and potential mechanisms in tumorigenesis and cancer progression of endometrial cancer (By Figdraw)

Although the close association between lipid metabolism reprogramming and EC has been established, there is still a long way to go to dissect the roles of lipid metabolism pathways. Firstly, to what degree the lipid uptake and its core driving molecules can be involved in the initiation and progression of EC remains contradictory. Next, the transcriptional factor, PPARs, show diverse expression profiles, which leads to the exploration of their precision targeting strategy challenging. What’s more, hormone in combination with lipid metabolism targeted treatment has been applied in clinical trials, but the definite efficacy of preventing endometrial malignant transformation and inhibiting cancer progression is awaiting robust evidence. More importantly, sensitizing immunotherapy by rewiring the lipid metabolism is a promising direction for advanced/metastatic EC management due to the encouragement of several clinical trials in other malignancies, and the theoretical basis and clinical benefits should be further determined.

In conclusion, lipid metabolism reprogramming has become a hallmark of EC, which not only participates in the occurrence and advancement of tumor, but also has proposed as an interventional strategy. As studies increasingly accumulate, it’s expected to depict a comprehensive landscape of lipid metabolism in EC. In the future, researchers should focus on clarifying the pathological roles of different branches of lipid metabolism pathway and their interaction with the tumor microenvironment, and developing novel targetable molecules to decrease the tumor burden and hinder the cancer progression.

Abbreviations

ABCA1 ATP binding cassette subfamily A member 1

ABCG1 ATP binding cassette subfamily G member 1

ACAT Acyl-CoA: cholesterol acyltransferase

ACC Acetyl-CoA carboxylase

ACLY ATP-citrate lyase

ACSS2 Acetyl-CoA synthetase 2

ACSL Long-chain acyl-CoA synthetase

CPT1 Carnitine palmitoyltransferase1

EC Endometrial cancer

EMT Epithelial-mesenchymal transition

FA Fatty acid

FAO Fatty acid oxidation

FASN Fatty acid synthase

FATP Fatty acid transport protein

HDL High-density lipoprotein

HMGCR 3-hydroxy-3-methyl glutaryl coenzyme A reductase

LDLR Low-density lipoprotein receptor

LDL-C Low-density lipoprotein-cholesterol

LXR Liver X receptor

MUFA Monounsaturated fatty acid

PPAR Peroxisome proliferator-activated receptor

PUFA Polyunsaturated fatty acid

SCD1 Stearic acid desaturase 1

SM Squalene monooxygenase

SQLE Squalene cyclooxygenase

SRE Sterol regulating element

SREBP Sterol regulatory element binding protein

Acknowledgements

Relevant clinical trial data were downloaded from https://clinicaltrials.gov/. All figures in the manuscript were created by Figdraw (https://www.figdraw.com/#/).

Authors’ contributions

Xiangyu Wang contributed to manuscript writing and visualization. Yinuo Li contributed to manuscript revision and editing. Xin Hou and Jingfang Li contributed to literature collection. Xiangyi Ma contributed to conceptualization and supervision. All authors listed have approved this manuscript.

Funding

This work was supported by the National Key Research & Development Program of China (grant ID: 2021YFC2701402).

Availability of data and materials

No datasets were generated or analysed during the current study.

Declarations

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Bray F Laversanne M Sung H Ferlay J Siegel RL Soerjomataram I Jemal A Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2024 74 3 229 263 10.3322/caac.21834 38572751
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.38572751 10.3322/caac.21834
2. Siegel RL Giaquinto AN Jemal A Cancer statistics, 2024 CA Cancer J Clin 2024 74 1 12 49 10.3322/caac.21820 38230766
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49.38230766 10.3322/caac.21820
3. Onstad MA Schmandt RE Lu KH Addressing the role of obesity in Endometrial Cancer Risk, Prevention, and treatment J Clin Oncol 2016 34 35 4225 30 10.1200/JCO.2016.69.4638 27903150
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in Endometrial Cancer Risk, Prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30.27903150 10.1200/JCO.2016.69.4638
4. Crosbie EJ Kitson SJ McAlpine JN Mukhopadhyay A Powell ME Singh N Endometrial cancer Lancet 2022 399 10333 1412 28 10.1016/S0140-6736(22)00323-3 35397864
Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.35397864 10.1016/S0140-6736(22)00323-3
5. Gordhandas S Zammarrelli WA Rios-Doria EV Green AK Makker V Current evidence-based systemic therapy for Advanced and recurrent endometrial Cancer J Natl Compr Canc Netw 2023 21 2 217 26 10.6004/jnccn.2022.7254 36791759
Gordhandas S, Zammarrelli WA, Rios-Doria EV, Green AK, Makker V. Current evidence-based systemic therapy for Advanced and recurrent endometrial Cancer. J Natl Compr Canc Netw. 2023;21(2):217–26.36791759 10.6004/jnccn.2022.7254
6. Brooks RA Fleming GF Lastra RR Lee NK Moroney JW Son CH Tatebe K Veneris JL Current recommendations and recent progress in endometrial cancer CA Cancer J Clin 2019 69 4 258 79 10.3322/caac.21561 31074865
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258–79.31074865 10.3322/caac.21561
7. Bogani G Monk BJ Powell MA Westin SN Slomovitz B Moore KN Eskander RN Raspagliesi F Barretina-Ginesta MP Colombo N Mirza MR Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer Ann Oncol 2024 35 5 414 28 10.1016/j.annonc.2024.02.006 38431043
Bogani G, Monk BJ, Powell MA, Westin SN, Slomovitz B, Moore KN, Eskander RN, Raspagliesi F, Barretina-Ginesta MP, Colombo N, Mirza MR. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol. 2024;35(5):414–28.38431043 10.1016/j.annonc.2024.02.006
8. Marín-Jiménez JA García-Mulero S Matías-Guiu X Piulats JM Facts and hopes in Immunotherapy of Endometrial Cancer Clin Cancer Res 2022 28 22 4849 60 10.1158/1078-0432.CCR-21-1564 35789264
Marín-Jiménez JA, García-Mulero S, Matías-Guiu X, Piulats JM. Facts and hopes in Immunotherapy of Endometrial Cancer. Clin Cancer Res. 2022;28(22):4849–60.35789264 10.1158/1078-0432.CCR-21-1564
9. Wang L Du ZH Qiao JM Gao S Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies Aging 2020 12 10 9825 39 10.18632/aging.103247 32439832
Wang L, Du ZH, Qiao JM, Gao S. Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies. Aging. 2020;12(10):9825–39.32439832 10.18632/aging.103247
10. Ding Y Fan Y Li X Wang Y Wang J Tian L Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients Reprod Biol Endocrinol 2022 20 1 134 10.1186/s12958-022-01006-0 36064542
Ding Y, Fan Y, Li X, Wang Y, Wang J, Tian L. Metabolic syndrome is an independent risk factor for time to complete remission of fertility-sparing treatment in atypical endometrial hyperplasia and early endometrial carcinoma patients. Reprod Biol Endocrinol. 2022;20(1):134.36064542 10.1186/s12958-022-01006-0
11. Rosato V Zucchetto A Bosetti C Dal Maso L Montella M Pelucchi C Negri E Franceschi S La Vecchia, metabolic syndrome and endometrial cancer risk Ann Oncol 2011 22 4 884 9 10.1093/annonc/mdq464 20937645
Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S. La Vecchia, metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22(4):884–9.20937645 10.1093/annonc/mdq464
12. Jo H Kim SI Wang W Seol A Han Y Kim J Park IS Lee J Yoo J Han KD Song YS Metabolic syndrome as a risk factor of Endometrial Cancer: a Nationwide Population-based Cohort Study of 2.8 million women in South Korea Front Oncol 2022 12 872995 10.3389/fonc.2022.872995 35785211
Jo H, Kim SI, Wang W, Seol A, Han Y, Kim J, Park IS, Lee J, Yoo J, Han KD, Song YS. Metabolic syndrome as a risk factor of Endometrial Cancer: a Nationwide Population-based Cohort Study of 2.8 million women in South Korea. Front Oncol. 2022;12:872995.35785211 10.3389/fonc.2022.872995
13. Nevadunsky NS Van Arsdale A Strickler HD Moadel A Kaur G Levitt J Girda E Goldfinger M Goldberg GL Einstein MH Obesity and age at diagnosis of endometrial cancer Obstet Gynecol 2014 124 2 Pt 1 300 6 10.1097/AOG.0000000000000381 25004350
Nevadunsky NS, Van Arsdale A, Strickler HD, Moadel A, Kaur G, Levitt J, Girda E, Goldfinger M, Goldberg GL, Einstein MH. Obesity and age at diagnosis of endometrial cancer. Obstet Gynecol. 2014;124(2 Pt 1):300–6.25004350 10.1097/AOG.0000000000000381
14. Zhang H Kong W Han C Liu T Li J Song D Correlation of metabolic factors with endometrial atypical Hyperplasia and Endometrial Cancer: Development and Assessment of a New Predictive Nomogram Cancer Manag Res 2021 13 7937 49 10.2147/CMAR.S335924 34703315
Zhang H, Kong W, Han C, Liu T, Li J, Song D. Correlation of metabolic factors with endometrial atypical Hyperplasia and Endometrial Cancer: Development and Assessment of a New Predictive Nomogram. Cancer Manag Res. 2021;13:7937–49.34703315 10.2147/CMAR.S335924
15. Bokhman JV Two pathogenetic types of endometrial carcinoma Gynecol Oncol 1983 15 1 10 7 10.1016/0090-8258(83)90111-7 6822361
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.6822361 10.1016/0090-8258(83)90111-7
16. Grandi G Perrone AM Chiossi G Friso S Toss A Sammarini M Facchinetti F Botticelli L Palma F De Iaco P Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study Gynecol Oncol 2019 154 1 163 8 10.1016/j.ygyno.2019.04.684 31104904
Grandi G, Perrone AM, Chiossi G, Friso S, Toss A, Sammarini M, Facchinetti F, Botticelli L, Palma F, De Iaco P. Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study. Gynecol Oncol. 2019;154(1):163–8.31104904 10.1016/j.ygyno.2019.04.684
17. Calle EE Rodriguez C Walker-Thurmond K Thun MJ Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 2003 348 17 1625 38 10.1056/NEJMoa021423 12711737
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.12711737 10.1056/NEJMoa021423
18. Pavlova NN Zhu J Thompson CB The hallmarks of cancer metabolism: still emerging Cell Metab 2022 34 3 355 77 10.1016/j.cmet.2022.01.007 35123658
Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355–77.35123658 10.1016/j.cmet.2022.01.007
19. Martínez-Reyes I Chandel NS Cancer metabolism: looking forward Nat Rev Cancer 2021 21 10 669 80 10.1038/s41568-021-00378-6 34272515
Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–80.34272515 10.1038/s41568-021-00378-6
20. Xia L Oyang L Lin J Tan S Han Y Wu N Yi P Tang L Pan Q Rao S Liang J Tang Y Su M Luo X Yang Y Shi Y Wang H Zhou Y Liao Q The cancer metabolic reprogramming and immune response Mol Cancer 2021 20 1 28 10.1186/s12943-021-01316-8 33546704
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, Yi P, Tang L, Pan Q, Rao S, Liang J, Tang Y, Su M, Luo X, Yang Y, Shi Y, Wang H, Zhou Y, Liao Q. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28.33546704 10.1186/s12943-021-01316-8
21. Bergers G Fendt SM The metabolism of cancer cells during metastasis Nat Rev Cancer 2021 21 3 162 80 10.1038/s41568-020-00320-2 33462499
Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162–80.33462499 10.1038/s41568-020-00320-2
22. Faubert B Solmonson A DeBerardinis RJ Metabolic reprogramming and cancer progression Science 2020 368 6487 eaaw5473 10.1126/science.aaw5473 32273439
Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.32273439 10.1126/science.aaw5473
23. Martin-Perez M Urdiroz-Urricelqui U Bigas C Benitah SA The role of lipids in cancer progression and metastasis Cell Metab 2022 34 11 1675 99 10.1016/j.cmet.2022.09.023 36261043
Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34(11):1675–99.36261043 10.1016/j.cmet.2022.09.023
24. Cheng C Geng F Cheng X Guo D Lipid metabolism reprogramming and its potential targets in cancer Cancer Commun (Lond) 2018 38 1 27 29784041
Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). 2018;38(1):27.29784041
25. Bian X Liu R Meng Y Xing D Xu D Lu Z Lipid metabolism and cancer J Exp Med 2021 218 1 e20201606 10.1084/jem.20201606 33601415
Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1):e20201606.33601415 10.1084/jem.20201606
26. Broadfield LA Pane AA Talebi A Swinnen JV Fendt SM Lipid metabolism in cancer: new perspectives and emerging mechanisms Dev Cell 2021 56 10 1363 93 10.1016/j.devcel.2021.04.013 33945792
Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56(10):1363–93.33945792 10.1016/j.devcel.2021.04.013
27. Koundouros N Poulogiannis G Reprogramming of fatty acid metabolism in cancer Br J Cancer 2020 122 1 4 22 10.1038/s41416-019-0650-z 31819192
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122(1):4–22.31819192 10.1038/s41416-019-0650-z
28. Snaebjornsson MT Janaki-Raman S Schulze A Greasing the Wheels of the Cancer machine: the role of lipid metabolism in Cancer Cell Metab 2020 31 1 62 76 10.1016/j.cmet.2019.11.010 31813823
Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the Wheels of the Cancer machine: the role of lipid metabolism in Cancer. Cell Metab. 2020;31(1):62–76.31813823 10.1016/j.cmet.2019.11.010
29. Hao JW Wang J Guo H Zhao YY Sun HH Li YF Lai XY Zhao N Wang X Xie C Hong L Huang X Wang HR Li CB Liang B Chen S Zhao TJ CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis Nat Commun 2020 11 1 4765 10.1038/s41467-020-18565-8 32958780
Hao JW, Wang J, Guo H, Zhao YY, Sun HH, Li YF, Lai XY, Zhao N, Wang X, Xie C, Hong L, Huang X, Wang HR, Li CB, Liang B, Chen S, Zhao TJ. CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis. Nat Commun. 2020;11(1):4765.32958780 10.1038/s41467-020-18565-8
30. Ruan C Meng Y Song H CD36: an emerging therapeutic target for cancer and its molecular mechanisms J Cancer Res Clin Oncol 2022 148 7 1551 8 10.1007/s00432-022-03957-8 35224665
Ruan C, Meng Y, Song H. CD36: an emerging therapeutic target for cancer and its molecular mechanisms. J Cancer Res Clin Oncol. 2022;148(7):1551–8.35224665 10.1007/s00432-022-03957-8
31. Wang J Li Y CD36 tango in cancer: signaling pathways and functions Theranostics 2019 9 17 4893 908 10.7150/thno.36037 31410189
Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Theranostics. 2019;9(17):4893–908.31410189 10.7150/thno.36037
32. Yang P Qin H Li Y Xiao A Zheng E Zeng H Su C Luo X Lu Q Liao M Zhao L Wei L Varghese Z Moorhead JF Chen Y Ruan XZ CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis Nat Commun 2022 13 1 5782 10.1038/s41467-022-33349-y 36184646
Yang P, Qin H, Li Y, Xiao A, Zheng E, Zeng H, Su C, Luo X, Lu Q, Liao M, Zhao L, Wei L, Varghese Z, Moorhead JF, Chen Y, Ruan XZ. CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis. Nat Commun. 2022;13(1):5782.36184646 10.1038/s41467-022-33349-y
33. Feng WW Wilkins O Bang S Ung M Li J An J Del Genio C Canfield K DiRenzo J Wells W Gaur A Robey RB Guo JY Powles RL Sotiriou C Pusztai L Febbraio M Cheng C Kinlaw WB Kurokawa M CD36-Mediated metabolic rewiring of breast Cancer cells promotes resistance to HER2-Targeted therapies Cell Rep 2019 29 11 3405 e34205 10.1016/j.celrep.2019.11.008 31825825
Feng WW, Wilkins O, Bang S, Ung M, Li J, An J, Del Genio C, Canfield K, DiRenzo J, Wells W, Gaur A, Robey RB, Guo JY, Powles RL, Sotiriou C, Pusztai L, Febbraio M, Cheng C, Kinlaw WB, Kurokawa M. CD36-Mediated metabolic rewiring of breast Cancer cells promotes resistance to HER2-Targeted therapies. Cell Rep. 2019;29(11):3405–e34205.31825825 10.1016/j.celrep.2019.11.008
34. Kubo M Gotoh K Eguchi H Kobayashi S Iwagami Y Tomimaru Y Akita H Asaoka T Noda T Takeda Y Tanemura M Mori M Doki Y Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma Ann Surg Oncol 2020 27 2 610 9 10.1245/s10434-019-07927-2 31605325
Kubo M, Gotoh K, Eguchi H, Kobayashi S, Iwagami Y, Tomimaru Y, Akita H, Asaoka T, Noda T, Takeda Y, Tanemura M, Mori M, Doki Y. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2020;27(2):610–9.31605325 10.1245/s10434-019-07927-2
35. Su T Huang C Yang C Jiang T Su J Chen M Fatima S Gong R Hu X Bian Z Liu Z Kwan HY Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity Pharmacol Res 2020 152 104586 10.1016/j.phrs.2019.104586 31877350
Su T, Huang C, Yang C, Jiang T, Su J, Chen M, Fatima S, Gong R, Hu X, Bian Z, Liu Z, Kwan HY. Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity. Pharmacol Res. 2020;152:104586.31877350 10.1016/j.phrs.2019.104586
36. Knapp P Chabowski A Harasiuk D Górski J Reversed glucose and fatty acids transporter expression in human endometrial cancer Horm Metab Res 2012 44 6 436 41 10.1055/s-0031-1301301 22351475
Knapp P, Chabowski A, Harasiuk D, Górski J. Reversed glucose and fatty acids transporter expression in human endometrial cancer. Horm Metab Res. 2012;44(6):436–41.22351475 10.1055/s-0031-1301301
37. McKillop IH Girardi CA Thompson KJ Role of fatty acid binding proteins (FABPs) in cancer development and progression Cell Signal 2019 62 109336 10.1016/j.cellsig.2019.06.001 31170472
McKillop IH, Girardi CA, Thompson KJ. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal. 2019;62:109336.31170472 10.1016/j.cellsig.2019.06.001
38. Tian W Zhang W Zhang Y Zhu T Hua Y Li H Zhang Q Xia M FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport Cancer Cell Int 2020 20 512 10.1186/s12935-020-01582-4 33088219
Tian W, Zhang W, Zhang Y, Zhu T, Hua Y, Li H, Zhang Q, Xia M. FABP4 promotes invasion and metastasis of colon cancer by regulating fatty acid transport. Cancer Cell Int. 2020;20:512.33088219 10.1186/s12935-020-01582-4
39. Tang Y Li K Hu B Cai Z Li J Tao H Cao J Fatty acid binding protein 5 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by degradation of Krüppel-like factor 9 mediated by mir-889-5p via cAMP-response element binding protein Cancer Biol Ther 2022 23 1 424 38 10.1080/15384047.2022.2094670 35816613
Tang Y, Li K, Hu B, Cai Z, Li J, Tao H, Cao J. Fatty acid binding protein 5 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by degradation of Krüppel-like factor 9 mediated by mir-889-5p via cAMP-response element binding protein. Cancer Biol Ther. 2022;23(1):424–38.35816613 10.1080/15384047.2022.2094670
40. Hao J Zhang Y Yan X Yan F Sun Y Zeng J Waigel S Yin Y Fraig MM Egilmez NK Suttles J Kong M Liu S Cleary MP Sauter E Li B Circulating adipose fatty acid binding protein is a New Link underlying obesity-Associated Breast/Mammary Tumor Development Cell Metab 2018 28 5 689 e7055 10.1016/j.cmet.2018.07.006 30100196
Hao J, Zhang Y, Yan X, Yan F, Sun Y, Zeng J, Waigel S, Yin Y, Fraig MM, Egilmez NK, Suttles J, Kong M, Liu S, Cleary MP, Sauter E, Li B. Circulating adipose fatty acid binding protein is a New Link underlying obesity-Associated Breast/Mammary Tumor Development. Cell Metab. 2018;28(5):689–e7055.30100196 10.1016/j.cmet.2018.07.006
41. Li Z Min W Huang C Bai S Tang M Zhao X Proteomics-based approach identified differentially expressed proteins with potential roles in endometrial carcinoma Int J Gynecol Cancer 2010 20 1 9 15 10.1111/IGC.0b013e3181a9026d 20057284
Li Z, Min W, Huang C, Bai S, Tang M, Zhao X. Proteomics-based approach identified differentially expressed proteins with potential roles in endometrial carcinoma. Int J Gynecol Cancer. 2010;20(1):9–15.20057284 10.1111/IGC.0b013e3181a9026d
42. Li Z Huang C Bai S Pan X Zhou R Wei Y Zhao X Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach Int J Cancer 2008 123 10 2377 83 10.1002/ijc.23808 18729184
Li Z, Huang C, Bai S, Pan X, Zhou R, Wei Y, Zhao X. Prognostic evaluation of epidermal fatty acid-binding protein and calcyphosine, two proteins implicated in endometrial cancer using a proteomic approach. Int J Cancer. 2008;123(10):2377–83.18729184 10.1002/ijc.23808
43. Wu Z Jeong JH Ren C Yang L Ding L Li F Jiang D Zhu Y Lu J Fatty acid-binding protein 4 (FABP4) suppresses Proliferation and Migration of Endometrial Cancer cells via PI3K/Akt pathway Onco Targets Ther 2021 14 3929 42 10.2147/OTT.S311792 34234461
Wu Z, Jeong JH, Ren C, Yang L, Ding L, Li F, Jiang D, Zhu Y, Lu J. Fatty acid-binding protein 4 (FABP4) suppresses Proliferation and Migration of Endometrial Cancer cells via PI3K/Akt pathway. Onco Targets Ther. 2021;14:3929–42.34234461 10.2147/OTT.S311792
44. Giacomini I Gianfanti F Desbats MA Orso G Berretta M Prayer-Galetti T Ragazzi E Cocetta V Cholesterol metabolic reprogramming in Cancer and its pharmacological modulation as therapeutic strategy Front Oncol 2021 11 682911 10.3389/fonc.2021.682911 34109128
Giacomini I, Gianfanti F, Desbats MA, Orso G, Berretta M, Prayer-Galetti T, Ragazzi E, Cocetta V. Cholesterol metabolic reprogramming in Cancer and its pharmacological modulation as therapeutic strategy. Front Oncol. 2021;11:682911.34109128 10.3389/fonc.2021.682911
45. Simons K Ehehalt R Cholesterol, lipid rafts, and disease J Clin Invest 2002 110 5 597 603 10.1172/JCI0216390 12208858
Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002;110(5):597–603.12208858 10.1172/JCI0216390
46. Ding X Zhang W Li S Yang H The role of cholesterol metabolism in cancer Am J Cancer Res 2019 9 2 219 27 30906624
Ding X, Zhang W, Li S, Yang H. The role of cholesterol metabolism in cancer. Am J Cancer Res. 2019;9(2):219–27.30906624
47. Gu J Zhu N Li HF Zhao TJ Zhang CJ Liao DF Qin L Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor Cell Oncol (Dordr) 2022 45 5 709 28 10.1007/s13402-022-00694-5 35864437
Gu J, Zhu N, Li HF, Zhao TJ, Zhang CJ, Liao DF, Qin L. Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. Cell Oncol (Dordr). 2022;45(5):709–28.35864437 10.1007/s13402-022-00694-5
48. Scully T Ettela A Kase N LeRoith D Gallagher EJ Unregulated LDL cholesterol uptake is detrimental to breast cancer cells Endocr Relat Cancer 2023 30 1 e220234 10.1530/ERC-22-0234 36256855
Scully T, Ettela A, Kase N, LeRoith D, Gallagher EJ. Unregulated LDL cholesterol uptake is detrimental to breast cancer cells. Endocr Relat Cancer. 2023;30(1):e220234.36256855 10.1530/ERC-22-0234
49. Kho PF Amant F Annibali D Ashton K Attia J Auer PL Beckmann MW Black A Brinton L Buchanan DD Chanock SJ Chen C Chen MM Cheng THT Cook LS Crous-Bous M Czene K De Vivo I Dennis J Dörk T Dowdy SC Dunning AM Dürst M Easton DF Ekici AB Fasching PA Fridley BL Friedenreich CM García-Closas M Gaudet MM Giles GG Goode EL Gorman M Haiman CA Hall P Hankinson SE Hein A Hillemanns P Hodgson S Hoivik EA Holliday EG Hunter DJ Jones A Kraft P Krakstad C Lambrechts D Le Marchand L Liang X Lindblom A Lissowska J Long J Lu L Magliocco AM Martin L McEvoy M Milne RL Mints M Nassir R Otton G Palles C Pooler L Proietto T Rebbeck TR Renner SP Risch HA Rübner M Runnebaum I Sacerdote C Sarto GE Schumacher F Scott RJ Setiawan VW Shah M Sheng X Shu XO Southey MC Tham E Tomlinson I Trovik J Turman C Tyrer JP Van Den Berg D Wang Z Wentzensen N Xia L Xiang YB Yang HP Yu H Zheng W Webb PM Thompson DJ Spurdle AB Glubb DM O’Mara TA Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer Int J Cancer. 2021 148 2 307 319 10.1002/ijc.33206 32851660
Kho PF, Amant F, Annibali D, Ashton K, Attia J, Auer PL, Beckmann MW, Black A, Brinton L, Buchanan DD, Chanock SJ, Chen C, Chen MM, Cheng THT, Cook LS, Crous-Bous M, Czene K, De Vivo I, Dennis J, Dörk T, Dowdy SC, Dunning AM, Dürst M, Easton DF, Ekici AB, Fasching PA, Fridley BL, Friedenreich CM, García-Closas M, Gaudet MM, Giles GG, Goode EL, Gorman M, Haiman CA, Hall P, Hankinson SE, Hein A, Hillemanns P, Hodgson S, Hoivik EA, Holliday EG, Hunter DJ, Jones A, Kraft P, Krakstad C, Lambrechts D, Le Marchand L, Liang X, Lindblom A, Lissowska J, Long J, Lu L, Magliocco AM, Martin L, McEvoy M, Milne RL, Mints M, Nassir R, Otton G, Palles C, Pooler L, Proietto T, Rebbeck TR, Renner SP, Risch HA, Rübner M, Runnebaum I, Sacerdote C, Sarto GE, Schumacher F, Scott RJ, Setiawan VW, Shah M, Sheng X, Shu XO, Southey MC, Tham E, Tomlinson I, Trovik J, Turman C, Tyrer JP, Van Den Berg D, Wang Z, Wentzensen N, Xia L, Xiang YB, Yang HP, Yu H, Zheng W, Webb PM, Thompson DJ, Spurdle AB, Glubb DM, O’Mara TA. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. Int J Cancer. 2021;148(2):307–19.32851660 10.1002/ijc.33206
50. He W Li Q Li X Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer Biochim Biophys Acta Rev Cancer 2023 1878 1 188837 10.1016/j.bbcan.2022.188837 36403921
He W, Li Q, Li X. Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878(1):188837.36403921 10.1016/j.bbcan.2022.188837
51. Schug ZT Peck B Jones DT Zhang Q Grosskurth S Alam IS Goodwin LM Smethurst E Mason S Blyth K McGarry L James D Shanks E Kalna G Saunders RE Jiang M Howell M Lassailly F Thin MZ Spencer-Dene B Stamp G van den Broek NJ Mackay G Bulusu V Kamphorst JJ Tardito S Strachan D Harris AL Aboagye EO Critchlow SE Wakelam MJ Schulze A Gottlieb E Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress Cancer Cell 2015 27 1 57 71 10.1016/j.ccell.2014.12.002 25584894
Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJ, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO, Critchlow SE, Wakelam MJ, Schulze A, Gottlieb E. Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 2015;27(1):57–71.25584894 10.1016/j.ccell.2014.12.002
52. Guertin DA Wellen KE Acetyl-CoA metabolism in cancer Nat Rev Cancer 2023 23 3 156 72 10.1038/s41568-022-00543-5 36658431
Guertin DA, Wellen KE. Acetyl-CoA metabolism in cancer. Nat Rev Cancer. 2023;23(3):156–72.36658431 10.1038/s41568-022-00543-5
53. Icard P Wu Z Fournel L Coquerel A Lincet H Alifano M ATP citrate lyase: a central metabolic enzyme in cancer Cancer Lett 2020 471 125 34 10.1016/j.canlet.2019.12.010 31830561
Icard P, Wu Z, Fournel L, Coquerel A, Lincet H, Alifano M. ATP citrate lyase: a central metabolic enzyme in cancer. Cancer Lett. 2020;471:125–34.31830561 10.1016/j.canlet.2019.12.010
54. Nwosu ZC Battello N Rothley M Piorońska W Sitek B Ebert MP Hofmann U Sleeman J Wölfl S Meyer C Megger DA Dooley S Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours J Exp Clin Cancer Res 2018 37 1 211 10.1186/s13046-018-0872-6 30176945
Nwosu ZC, Battello N, Rothley M, Piorońska W, Sitek B, Ebert MP, Hofmann U, Sleeman J, Wölfl S, Meyer C, Megger DA, Dooley S. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours. J Exp Clin Cancer Res. 2018;37(1):211.30176945 10.1186/s13046-018-0872-6
55. Chen Y Li K Gong D Zhang J Li Q Zhao G Lin P A biomarker of recurrence in breast cancer Pathol Res Pract 2020 216 9 153076 10.1016/j.prp.2020.153076 32825949
Chen Y, Li K, Gong D, Zhang J, Li Q, Zhao G, Lin P. A biomarker of recurrence in breast cancer. Pathol Res Pract. 2020;216(9):153076.32825949 10.1016/j.prp.2020.153076
56. Liu Q Ge W Wang T Lan J Martínez-Jarquín S Wolfrum C Stoffel M Zenobi R High-throughput single-cell Mass Spectrometry reveals abnormal lipid metabolism in pancreatic ductal adenocarcinoma Angew Chem Int Ed Engl 2021 60 46 24534 42 10.1002/anie.202107223 34505339
Liu Q, Ge W, Wang T, Lan J, Martínez-Jarquín S, Wolfrum C, Stoffel M, Zenobi R. High-throughput single-cell Mass Spectrometry reveals abnormal lipid metabolism in pancreatic ductal adenocarcinoma. Angew Chem Int Ed Engl. 2021;60(46):24534–42.34505339 10.1002/anie.202107223
57. Adorno-Cruz V Hoffmann AD Liu X Dashzeveg NK Taftaf R Wray B Keri RA Liu H ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis Genes Dis 2021 8 4 493 508 10.1016/j.gendis.2020.01.015 34179312
Adorno-Cruz V, Hoffmann AD, Liu X, Dashzeveg NK, Taftaf R, Wray B, Keri RA, Liu H. ITGA2 promotes expression of ACLY and CCND1 in enhancing breast cancer stemness and metastasis. Genes Dis. 2021;8(4):493–508.34179312 10.1016/j.gendis.2020.01.015
58. Guo H Wang B Xu K Nie L Fu Y Wang Z Wang Q Wang S Zou X M(6)a reader HNRNPA2B1 promotes esophageal Cancer Progression via Up-Regulation of ACLY and ACC1 Front Oncol 2020 10 553045 10.3389/fonc.2020.553045 33134163
Guo H, Wang B, Xu K, Nie L, Fu Y, Wang Z, Wang Q, Wang S, Zou X. M(6)a reader HNRNPA2B1 promotes esophageal Cancer Progression via Up-Regulation of ACLY and ACC1. Front Oncol. 2020;10:553045.33134163 10.3389/fonc.2020.553045
59. Qiao C Huang W Chen J Feng W Zhang T Wang Y Liu D Ji X Xie M Sun M Fan D Wu K Xia L IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R Cell Death Dis 2021 12 6 564 10.1038/s41419-021-03833-2 34075028
Qiao C, Huang W, Chen J, Feng W, Zhang T, Wang Y, Liu D, Ji X, Xie M, Sun M, Fan D, Wu K, Xia L. IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R. Cell Death Dis. 2021;12(6):564.34075028 10.1038/s41419-021-03833-2
60. Noh KH Kang HM Yoo W Min Y Kim D Kim M Wang S Lim JH Jung CR Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression Metabolism 2020 110 154302 10.1016/j.metabol.2020.154302 32589900
Noh KH, Kang HM, Yoo W, Min Y, Kim D, Kim M, Wang S, Lim JH, Jung CR. Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression. Metabolism. 2020;110:154302.32589900 10.1016/j.metabol.2020.154302
61. Dai M Yang B Chen J Liu F Zhou Y Zhou Y Xu Q Jiang S Zhao S Li X Zhou X Yang Q Li J Wang Y Zhang Z Teng Y Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer Cancer Lett 2021 513 36 49 10.1016/j.canlet.2021.04.024 33991616
Dai M, Yang B, Chen J, Liu F, Zhou Y, Zhou Y, Xu Q, Jiang S, Zhao S, Li X, Zhou X, Yang Q, Li J, Wang Y, Zhang Z, Teng Y. Nuclear-translocation of ACLY induced by obesity-related factors enhances pyrimidine metabolism through regulating histone acetylation in endometrial cancer. Cancer Lett. 2021;513:36–49.33991616 10.1016/j.canlet.2021.04.024
62. Kumari R Deshmukh RS Das S Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis Nat Commun 2019 10 1 4255 10.1038/s41467-019-12194-6 31534141
Kumari R, Deshmukh RS, Das S. Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis. Nat Commun. 2019;10(1):4255.31534141 10.1038/s41467-019-12194-6
63. Ly CH Lynch GS Ryall JG A metabolic Roadmap for somatic stem cell fate Cell Metab 2020 31 6 1052 67 10.1016/j.cmet.2020.04.022 32433923
Ly CH, Lynch GS, Ryall JG. A metabolic Roadmap for somatic stem cell fate. Cell Metab. 2020;31(6):1052–67.32433923 10.1016/j.cmet.2020.04.022
64. Zhao S Torres A Henry RA Trefely S Wallace M Lee JV Carrer A Sengupta A Campbell SL Kuo YM Frey AJ Meurs N Viola JM Blair IA Weljie AM Metallo CM Snyder NW Andrews AJ Wellen, ATP-Citrate lyase controls a glucose-to-acetate metabolic switch Cell Rep 2016 17 4 1037 52 10.1016/j.celrep.2016.09.069 27760311
Zhao S, Torres A, Henry RA, Trefely S, Wallace M, Lee JV, Carrer A, Sengupta A, Campbell SL, Kuo YM, Frey AJ, Meurs N, Viola JM, Blair IA, Weljie AM, Metallo CM, Snyder NW, Andrews AJ. Wellen, ATP-Citrate lyase controls a glucose-to-acetate metabolic switch. Cell Rep. 2016;17(4):1037–52.27760311 10.1016/j.celrep.2016.09.069
65. Comerford SA Huang Z Du X Wang Y Cai L Witkiewicz AK Walters H Tantawy MN Fu A Manning HC Horton JD Hammer RE McKnight SL Tu BP Acetate dependence of tumors Cell 2014 159 7 1591 602 10.1016/j.cell.2014.11.020 25525877
Comerford S.A., Huang Z, Du X, Wang Y, Cai L, Witkiewicz A.K., Walters H, Tantawy M.N., Fu A, Manning H.C., Horton J.D., Hammer R.E., McKnight S.L., Tu B.P. Acetate dependence of tumors. Cell. 2014;159(7):1591–602.25525877 10.1016/j.cell.2014.11.020
66. Liu M Liu N Wang J Fu S Wang X Chen D Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism Cancers (Basel) 2022 14 12 2896 10.3390/cancers14122896 35740562
Liu M, Liu N, Wang J, Fu S, Wang X, Chen D. Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism. Cancers (Basel). 2022;14(12):2896.35740562 10.3390/cancers14122896
67. Li Z Liu H He J Wang Z Yin Z You G Wang Z Davis RE Lin P Bergsagel PL Manasanch EE Wong STC Esnaola NF Chang JC Orlowski RZ Yi Q Yang J Acetyl-CoA synthetase 2: a critical linkage in obesity-Induced Tumorigenesis in Myeloma Cell Metab 2021 33 1 78 e937 10.1016/j.cmet.2020.12.011 33406405
Li Z, Liu H, He J, Wang Z, Yin Z, You G, Wang Z, Davis RE, Lin P, Bergsagel PL, Manasanch EE, Wong STC, Esnaola NF, Chang JC, Orlowski RZ, Yi Q, Yang J. Acetyl-CoA synthetase 2: a critical linkage in obesity-Induced Tumorigenesis in Myeloma. Cell Metab. 2021;33(1):78–e937.33406405 10.1016/j.cmet.2020.12.011
68. Yu Y Nie Q Wang Z Di Y Chen X Ren K Targeting acetyl-CoA carboxylase 1 for cancer therapy Front Pharmacol 2023 14 1129010 10.3389/fphar.2023.1129010 36843935
Yu Y, Nie Q, Wang Z, Di Y, Chen X, Ren K. Targeting acetyl-CoA carboxylase 1 for cancer therapy. Front Pharmacol. 2023;14:1129010.36843935 10.3389/fphar.2023.1129010
69. Hunkeler M Hagmann A Stuttfeld E Chami M Guri Y Stahlberg H Maier T Structural basis for regulation of human acetyl-CoA carboxylase Nature 2018 558 7710 470 4 10.1038/s41586-018-0201-4 29899443
Hunkeler M, Hagmann A, Stuttfeld E, Chami M, Guri Y, Stahlberg H, Maier T. Structural basis for regulation of human acetyl-CoA carboxylase. Nature. 2018;558(7710):470–4.29899443 10.1038/s41586-018-0201-4
70. Lally JSV Ghoshal S DePeralta DK Moaven O Wei L Masia R Erstad DJ Fujiwara N Leong V Houde VP Anagnostopoulos AE Wang A Broadfield LA Ford RJ Foster RA Bates J Sun H Wang T Liu H Ray AS Saha AK Greenwood J Bhat S Harriman G Miao W Rocnik JL Westlin WF Muti P Tsakiridis T Harwood HJ Jr Kapeller R Hoshida Y Tanabe KK Steinberg GR Fuchs BC Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and Hepatocellular Carcinoma Cell Metab 2019 29 1 174 e1825 10.1016/j.cmet.2018.08.020 30244972
Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, Erstad DJ, Fujiwara N, Leong V, Houde VP, Anagnostopoulos AE, Wang A, Broadfield LA, Ford RJ, Foster RA, Bates J, Sun H, Wang T, Liu H, Ray AS, Saha AK, Greenwood J, Bhat S, Harriman G, Miao W, Rocnik JL, Westlin WF, Muti P, Tsakiridis T, Harwood HJ Jr., Kapeller R, Hoshida Y, Tanabe KK, Steinberg GR, Fuchs BC. Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and Hepatocellular Carcinoma. Cell Metab. 2019;29(1):174–e1825.30244972 10.1016/j.cmet.2018.08.020
71. Byrne FL Poon IK Modesitt SC Tomsig JL Chow JD Healy ME Baker WD Atkins KA Lancaster JM Marchion DC Moley KH Ravichandran KS Slack-Davis JK Hoehn KL Metabolic vulnerabilities in endometrial cancer Cancer Res 2014 74 20 5832 45 10.1158/0008-5472.CAN-14-0254 25205105
Byrne FL, Poon IK, Modesitt SC, Tomsig JL, Chow JD, Healy ME, Baker WD, Atkins KA, Lancaster JM, Marchion DC, Moley KH, Ravichandran KS, Slack-Davis JK, Hoehn KL. Metabolic vulnerabilities in endometrial cancer. Cancer Res. 2014;74(20):5832–45.25205105 10.1158/0008-5472.CAN-14-0254
72. Modesitt SC Hsu JY Chowbina SR Lawrence RT Hoehn KL Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer Int J Gynecol Cancer 2012 22 5 732 41 10.1097/IGC.0b013e3182510496 22635025
Modesitt SC, Hsu JY, Chowbina SR, Lawrence RT, Hoehn KL. Not all fat is equal: differential gene expression and potential therapeutic targets in subcutaneous adipose, visceral adipose, and endometrium of obese women with and without endometrial cancer. Int J Gynecol Cancer. 2012;22(5):732–41.22635025 10.1097/IGC.0b013e3182510496
73. Fhu CW Ali A Fatty Acid Synthase: An Emerging Target in Cancer Molecules 2020 25 17 3935 10.3390/molecules25173935 32872164
Fhu CW, Ali A. Fatty Acid Synthase: An Emerging Target in Cancer. Molecules. 2020;25(17):3935.32872164 10.3390/molecules25173935
74. Anagnostou E Miliaras D Meditskou S Grimbizis G Immunohistochemical investigation of metabolic markers fatty acid synthase (FASN) and glucose transporter 1 (GLUT1) in normal endometrium, endometrial hyperplasia, and endometrial malignancy Hippokratia 2017 21 4 169 74 30944506
Anagnostou E, Miliaras D, Meditskou S, Grimbizis G. Immunohistochemical investigation of metabolic markers fatty acid synthase (FASN) and glucose transporter 1 (GLUT1) in normal endometrium, endometrial hyperplasia, and endometrial malignancy. Hippokratia. 2017;21(4):169–74.30944506
75. Tsuji T Yoshinaga M Togami S Douchi T Nagata Y Fatty acid synthase expression and clinicopathological findings in endometrial cancer Acta Obstet Gynecol Scand 2004 83 6 586 90 10.1111/j.0001-6349.2004.00511.x 15144342
Tsuji T, Yoshinaga M, Togami S, Douchi T, Nagata Y. Fatty acid synthase expression and clinicopathological findings in endometrial cancer. Acta Obstet Gynecol Scand. 2004;83(6):586–90.15144342 10.1111/j.0001-6349.2004.00511.x
76. Sebastiani V Visca P Botti C Santeusanio G Galati GM Piccini V Capezzone B de Joannon U Di Tondo PL Alo Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma Gynecol Oncol 2004 92 1 101 5 10.1016/j.ygyno.2003.10.027 14751145
Sebastiani V, Visca P, Botti C, Santeusanio G, Galati GM, Piccini V, Capezzone B, de Joannon U, Di Tondo PL, Alo. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecol Oncol. 2004;92(1):101–5.14751145 10.1016/j.ygyno.2003.10.027
77. He Y Xu S Qi Y Tian J Xu F Long noncoding RNA SNHG25 promotes the malignancy of endometrial cancer by sponging microRNA-497-5p and increasing FASN expression J Ovarian Res 2021 14 1 163 10.1186/s13048-021-00906-w 34789312
He Y, Xu S, Qi Y, Tian J, Xu F. Long noncoding RNA SNHG25 promotes the malignancy of endometrial cancer by sponging microRNA-497-5p and increasing FASN expression. J Ovarian Res. 2021;14(1):163.34789312 10.1186/s13048-021-00906-w
78. Meijuan C Fang L Min F Qian W Hypomethylated gene RAC3 induces cell proliferation and invasion by increasing FASN expression in endometrial cancer Int J Biochem Cell Biol 2022 150 106274 10.1016/j.biocel.2022.106274 35917927
Meijuan C, Fang L, Min F, Qian W. Hypomethylated gene RAC3 induces cell proliferation and invasion by increasing FASN expression in endometrial cancer. Int J Biochem Cell Biol. 2022;150:106274.35917927 10.1016/j.biocel.2022.106274
79. Menendez JA Oza BP Atlas E Verma VA Mehmi I Lupu R Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells Oncogene 2004 23 28 4945 58 10.1038/sj.onc.1207476 15094777
Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells. Oncogene. 2004;23(28):4945–58.15094777 10.1038/sj.onc.1207476
80. Kubota CS Espenshade PJ Targeting Stearoyl-CoA desaturase in solid tumors Cancer Res 2022 82 9 1682 8 10.1158/0008-5472.CAN-21-4044 35294526
Kubota CS, Espenshade PJ. Targeting Stearoyl-CoA desaturase in solid tumors. Cancer Res. 2022;82(9):1682–8.35294526 10.1158/0008-5472.CAN-21-4044
81. Tracz-Gaszewska Z Dobrzyn P Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer Cancers (Basel) 2019 11 7 948 10.3390/cancers11070948 31284458
Tracz-Gaszewska Z, Dobrzyn P. Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer. Cancers (Basel). 2019;11(7):948.31284458 10.3390/cancers11070948
82. Tesfay L Paul BT Konstorum A Deng Z Cox AO Lee J Furdui CM Hegde P Torti FM Torti, Stearoyl-CoA desaturase 1 protects ovarian Cancer cells from ferroptotic cell death Cancer Res 2019 79 20 5355 66 10.1158/0008-5472.CAN-19-0369 31270077
Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, Furdui CM, Hegde P, Torti FM. Torti, Stearoyl-CoA desaturase 1 protects ovarian Cancer cells from ferroptotic cell death. Cancer Res. 2019;79(20):5355–66.31270077 10.1158/0008-5472.CAN-19-0369
83. Wang C Shi M Ji J Cai Q Zhao Q Jiang J Liu J Zhang H Zhu Z Zhang J Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer Aging 2020 12 15 15374 91 10.18632/aging.103598 32726752
Wang C, Shi M, Ji J, Cai Q, Zhao Q, Jiang J, Liu J, Zhang H, Zhu Z, Zhang J. Stearoyl-CoA desaturase 1 (SCD1) facilitates the growth and anti-ferroptosis of gastric cancer cells and predicts poor prognosis of gastric cancer. Aging. 2020;12(15):15374–91.32726752 10.18632/aging.103598
84. Luis G Godfroid A Nishiumi S Cimino J Blacher S Maquoi E Wery C Collignon A Longuespée R Montero-Ruiz L Dassoul I Maloujahmoum N Pottier C Mazzucchelli G Depauw E Bellahcène A Yoshida M Noel A Sounni NE Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and fatty acid biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence Redox Biol 2021 43 102006 10.1016/j.redox.2021.102006 34030117
Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, Wery C, Collignon A, Longuespée R, Montero-Ruiz L, Dassoul I, Maloujahmoum N, Pottier C, Mazzucchelli G, Depauw E, Bellahcène A, Yoshida M, Noel A, Sounni NE. Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and fatty acid biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021;43:102006.34030117 10.1016/j.redox.2021.102006
85. Ding Z Pan Y Shang T Jiang T Lin Y Yang C Pang S Cui X Wang Y Feng XF Xu M Pei M Chen Y Li X Ding J Tan Y Wang H Dong L Wang L URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers Nat Commun 2023 14 1 6269 10.1038/s41467-023-41852-z 37805657
Ding Z, Pan Y, Shang T, Jiang T, Lin Y, Yang C, Pang S, Cui X, Wang Y, Feng XF, Xu M, Pei M, Chen Y, Li X, Ding J, Tan Y, Wang H, Dong L, Wang L. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. 2023;14(1):6269.37805657 10.1038/s41467-023-41852-z
86. Li W Bai H Liu S Cao D Wu H Shen K Tai Y Yang J Targeting stearoyl-CoA desaturase 1 to repress endometrial cancer progression Oncotarget 2018 9 15 12064 78 10.18632/oncotarget.24304 29552293
Li W, Bai H, Liu S, Cao D, Wu H, Shen K, Tai Y, Yang J. Targeting stearoyl-CoA desaturase 1 to repress endometrial cancer progression. Oncotarget. 2018;9(15):12064–78.29552293 10.18632/oncotarget.24304
87. Xu H Zhou S Tang Q Xia H Bi F Cholesterol metabolism: new functions and therapeutic approaches in cancer Biochim Biophys Acta Rev Cancer 2020 1874 1 188394 10.1016/j.bbcan.2020.188394 32698040
Xu H, Zhou S, Tang Q, Xia H, Bi F. Cholesterol metabolism: new functions and therapeutic approaches in cancer. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188394.32698040 10.1016/j.bbcan.2020.188394
88. Qiu Z Yuan W Chen T Zhou C Liu C Huang Y Han D Huang Q HMGCR positively regulated the growth and migration of glioblastoma cells Gene 2016 576 1 Pt 1 22 7 10.1016/j.gene.2015.09.067 26432005
Qiu Z, Yuan W, Chen T, Zhou C, Liu C, Huang Y, Han D, Huang Q. HMGCR positively regulated the growth and migration of glioblastoma cells. Gene. 2016;576(1 Pt 1):22–7.26432005 10.1016/j.gene.2015.09.067
89. Chushi L Wei W Kangkang X Yongzeng F Ning X Xiaolei C HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells Gene 2016 587 1 42 7 10.1016/j.gene.2016.04.029 27085483
Chushi L, Wei W, Kangkang X, Yongzeng F, Ning X, Xiaolei C. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells. Gene. 2016;587(1):42–7.27085483 10.1016/j.gene.2016.04.029
90. Orho-Melander M Hindy G Borgquist S Schulz CA Manjer J Melander O Stocks T Blood lipid genetic scores, the HMGCR gene and cancer risk: a mendelian randomization study Int J Epidemiol 2018 47 2 495 505 10.1093/ije/dyx237 29165714
Orho-Melander M, Hindy G, Borgquist S, Schulz CA, Manjer J, Melander O, Stocks T. Blood lipid genetic scores, the HMGCR gene and cancer risk: a mendelian randomization study. Int J Epidemiol. 2018;47(2):495–505.29165714 10.1093/ije/dyx237
91. Bjarnadottir O Feldt M Inasu M Bendahl PO Elebro K Kimbung S Borgquist S Statin use, HMGCR expression, and breast cancer survival - the Malmö Diet and Cancer Study Sci Rep 2020 10 1 558 10.1038/s41598-019-57323-9 31953433
Bjarnadottir O, Feldt M, Inasu M, Bendahl PO, Elebro K, Kimbung S, Borgquist S. Statin use, HMGCR expression, and breast cancer survival - the Malmö Diet and Cancer Study. Sci Rep. 2020;10(1):558.31953433 10.1038/s41598-019-57323-9
92. Che L Chi W Qiao Y Zhang J Song X Liu Y Li L Jia J Pilo MG Wang J Cigliano A Ma Z Kuang W Tang Z Zhang Z Shui G Ribback S Dombrowski F Evert M Pascale RM Cossu C Pes GM Osborne TF Calvisi DF Chen X Chen L Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans Gut 2020 69 1 177 86 10.1136/gutjnl-2018-317581 30954949
Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, Li L, Jia J, Pilo MG, Wang J, Cigliano A, Ma Z, Kuang W, Tang Z, Zhang Z, Shui G, Ribback S, Dombrowski F, Evert M, Pascale RM, Cossu C, Pes GM, Osborne TF, Calvisi DF, Chen X, Chen L. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69(1):177–86.30954949 10.1136/gutjnl-2018-317581
93. Yarmolinsky J Bull CJ Vincent EE Robinson J Walther A Smith GD Lewis SJ Relton CL Martin RM Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian Cancer JAMA 2020 323 7 646 55 10.1001/jama.2020.0150 32068819
Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, Lewis SJ, Relton CL, Martin RM. Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian Cancer. JAMA. 2020;323(7):646–55.32068819 10.1001/jama.2020.0150
94. Sun L Ding H Jia Y Shi M Guo D Yang P Wang Y Liu F Zhang Y Zhu Z Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer Breast Cancer Res 2022 24 1 12 10.1186/s13058-022-01508-0 35151363
Sun L, Ding H, Jia Y, Shi M, Guo D, Yang P, Wang Y, Liu F, Zhang Y, Zhu Z. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Breast Cancer Res. 2022;24(1):12.35151363 10.1186/s13058-022-01508-0
95. Wang G Liu X Wang D Sun M Yang Q Identification and development of subtypes with poor prognosis in Pan-gynecological Cancer based on Gene expression in the glycolysis-cholesterol synthesis Axis Front Oncol 2021 11 636565 10.3389/fonc.2021.636565 33842342
Wang G, Liu X, Wang D, Sun M, Yang Q. Identification and development of subtypes with poor prognosis in Pan-gynecological Cancer based on Gene expression in the glycolysis-cholesterol synthesis Axis. Front Oncol. 2021;11:636565.33842342 10.3389/fonc.2021.636565
96. Zhang HY Li HM Yu Z Yu XY Guo K Expression and significance of squalene epoxidase in squamous lung cancerous tissues and pericarcinoma tissues Thorac Cancer 2014 5 4 275 80 10.1111/1759-7714.12087 26767013
Zhang HY, Li HM, Yu Z, Yu XY, Guo K. Expression and significance of squalene epoxidase in squamous lung cancerous tissues and pericarcinoma tissues. Thorac Cancer. 2014;5(4):275–80.26767013 10.1111/1759-7714.12087
97. Kim NI Park MH Kweon SS Cho N Lee JS Squalene epoxidase expression is associated with breast tumor progression and with a poor prognosis in breast cancer Oncol Lett 2021 21 4 259 10.3892/ol.2021.12520 33664822
Kim NI, Park MH, Kweon SS, Cho N, Lee JS. Squalene epoxidase expression is associated with breast tumor progression and with a poor prognosis in breast cancer. Oncol Lett. 2021;21(4):259.33664822 10.3892/ol.2021.12520
98. Li C Wang Y Liu D Wong CC Coker OO Zhang X Liu C Zhou Y Liu Y Kang W To KF Sung JJ Yu J Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis Gut 2022 71 11 2253 65 10.1136/gutjnl-2021-325851 35232776
Li C, Wang Y, Liu D, Wong CC, Coker OO, Zhang X, Liu C, Zhou Y, Liu Y, Kang W, To KF, Sung JJ, Yu J. Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis. Gut. 2022;71(11):2253–65.35232776 10.1136/gutjnl-2021-325851
99. Jiang H Tang E Chen Y Liu H Zhao Y Lin M He L Squalene synthase predicts poor prognosis in stage I-III colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression Cancer Sci 2022 113 3 971 85 10.1111/cas.15248 34939274
Jiang H, Tang E, Chen Y, Liu H, Zhao Y, Lin M, He L. Squalene synthase predicts poor prognosis in stage I-III colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression. Cancer Sci. 2022;113(3):971–85.34939274 10.1111/cas.15248
100. Kalogirou C Linxweiler J Schmucker P Snaebjornsson MT Schmitz W Wach S Krebs M Hartmann E Puhr M Müller A Spahn M Seitz AK Frank T Marouf H Büchel G Eckstein M Kübler H Eilers M Saar M Junker K Röhrig F Kneitz B Rosenfeldt MT Schulze A MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer Nat Commun 2021 12 1 5066 10.1038/s41467-021-25325-9 34417456
Kalogirou C, Linxweiler J, Schmucker P, Snaebjornsson MT, Schmitz W, Wach S, Krebs M, Hartmann E, Puhr M, Müller A, Spahn M, Seitz AK, Frank T, Marouf H, Büchel G, Eckstein M, Kübler H, Eilers M, Saar M, Junker K, Röhrig F, Kneitz B, Rosenfeldt MT, Schulze A. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 2021;12(1):5066.34417456 10.1038/s41467-021-25325-9
101. Ma L Huang W Liang X Bai G Wang X Jiang H Xin Y Hu L Chen X Liu C Inhibition of squalene epoxidase linking with PI3K/AKT signaling pathway suppresses endometrial cancer Cancer Sci 2023 114 9 3595 607 10.1111/cas.15900 37438885
Ma L, Huang W, Liang X, Bai G, Wang X, Jiang H, Xin Y, Hu L, Chen X, Liu C. Inhibition of squalene epoxidase linking with PI3K/AKT signaling pathway suppresses endometrial cancer. Cancer Sci. 2023;114(9):3595–607.37438885 10.1111/cas.15900
102. Coates HW Nguyen TB Du X Olzomer EM Farrell R Byrne FL Yang H Brown AJ The constitutively active form of a key cholesterol synthesis enzyme is lipid droplet-localized and upregulated in endometrial cancer tissues J Biol Chem 2024 300 5 107232 10.1016/j.jbc.2024.107232 38537696
Coates HW, Nguyen TB, Du X, Olzomer EM, Farrell R, Byrne FL, Yang H, Brown AJ. The constitutively active form of a key cholesterol synthesis enzyme is lipid droplet-localized and upregulated in endometrial cancer tissues. J Biol Chem. 2024;300(5):107232.38537696 10.1016/j.jbc.2024.107232
103. Luo J Yang H Song BL Mechanisms and regulation of cholesterol homeostasis Nat Rev Mol Cell Biol 2020 21 4 225 45 10.1038/s41580-019-0190-7 31848472
Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225–45.31848472 10.1038/s41580-019-0190-7
104. Bhattacharjee P Rutland N Iyer MR Targeting sterol O-Acyltransferase/Acyl-CoA:cholesterol acyltransferase (ACAT): a perspective on small-molecule inhibitors and their therapeutic potential J Med Chem 2022 65 24 16062 98 10.1021/acs.jmedchem.2c01265 36473091
Bhattacharjee P, Rutland N, Iyer MR. Targeting sterol O-Acyltransferase/Acyl-CoA:cholesterol acyltransferase (ACAT): a perspective on small-molecule inhibitors and their therapeutic potential. J Med Chem. 2022;65(24):16062–98.36473091 10.1021/acs.jmedchem.2c01265
105. Eckhardt C Sbiera I Krebs M Sbiera S Spahn M Kneitz B Joniau S Fassnacht M Kübler H Weigand I Kroiss M High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer Prostate Cancer Prostatic Dis 2022 25 3 484 90 10.1038/s41391-021-00431-3 34326474
Eckhardt C, Sbiera I, Krebs M, Sbiera S, Spahn M, Kneitz B, Joniau S, Fassnacht M, Kübler H, Weigand I, Kroiss M. High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. Prostate Cancer Prostatic Dis. 2022;25(3):484–90.34326474 10.1038/s41391-021-00431-3
106. Omsjø IH Norum KR Cholesterol esterification in human secretory endometrium and in endometrial cancer tissue. Demonstration of microsomal acyl-CoA-cholesterol acyl-transferase (ACAT) activity Acta Obstet Gynecol Scand 1985 64 6 473 6 10.3109/00016348509156724 4061064
Omsjø IH, Norum KR. Cholesterol esterification in human secretory endometrium and in endometrial cancer tissue. Demonstration of microsomal acyl-CoA-cholesterol acyl-transferase (ACAT) activity. Acta Obstet Gynecol Scand. 1985;64(6):473–6.4061064 10.3109/00016348509156724
107. Chen Y Lee K Liang Y Qin S Zhu Y Liu J Yao S A cholesterol homeostasis-related gene signature predicts prognosis of Endometrial Cancer and correlates with Immune Infiltration Front Genet 2021 12 763537 10.3389/fgene.2021.763537 34790227
Chen Y, Lee K, Liang Y, Qin S, Zhu Y, Liu J, Yao S. A cholesterol homeostasis-related gene signature predicts prognosis of Endometrial Cancer and correlates with Immune Infiltration. Front Genet. 2021;12:763537.34790227 10.3389/fgene.2021.763537
108. Ma Y Temkin SM Hawkridge AM Guo C Wang W Wang XY Fang X Fatty acid oxidation: an emerging facet of metabolic transformation in cancer Cancer Lett 2018 435 92 100 10.1016/j.canlet.2018.08.006 30102953
Ma Y, Temkin SM, Hawkridge AM, Guo C, Wang W, Wang XY, Fang X. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92–100.30102953 10.1016/j.canlet.2018.08.006
109. Quan J Cheng C Tan Y Jiang N Liao C Liao W Cao Y Luo X Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFβ1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma Int J Biol Sci 2022 18 6 2484 96 10.7150/ijbs.69802 35414781
Quan J, Cheng C, Tan Y, Jiang N, Liao C, Liao W, Cao Y, Luo X. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFβ1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma. Int J Biol Sci. 2022;18(6):2484–96.35414781 10.7150/ijbs.69802
110. Tang M Dong X Xiao L Tan Z Luo X Yang L Li W Shi F Li Y Zhao L Liu N Du Q Xie L Hu J Weng X Fan J Zhou J Gao Q Wu W Zhang X Liao W Bode AM Cao Y CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma Cell Death Dis 2022 13 4 331 10.1038/s41419-022-04730-y 35411000
Tang M, Dong X, Xiao L, Tan Z, Luo X, Yang L, Li W, Shi F, Li Y, Zhao L, Liu N, Du Q, Xie L, Hu J, Weng X, Fan J, Zhou J, Gao Q, Wu W, Zhang X, Liao W, Bode AM, Cao Y. CPT1A-mediated fatty acid oxidation promotes cell proliferation via nucleoside metabolism in nasopharyngeal carcinoma. Cell Death Dis. 2022;13(4):331.35411000 10.1038/s41419-022-04730-y
111. Zhou Y Li Y Chen G Guo X Gao X Meng J Xu Y Zhou N Zhang B Zhou X ACSL1-Mediated fatty acid β-Oxidation enhances metastasis and proliferation in Endometrial Cancer Front Biosci (Landmark Ed) 2024 29 2 66 10.31083/j.fbl2902066 38420815
Zhou Y, Li Y, Chen G, Guo X, Gao X, Meng J, Xu Y, Zhou N, Zhang B, Zhou X. ACSL1-Mediated fatty acid β-Oxidation enhances metastasis and proliferation in Endometrial Cancer. Front Biosci (Landmark Ed). 2024;29(2):66.38420815 10.31083/j.fbl2902066
112. Yu Y Sun X Chen F Liu M Genetic alteration, prognostic and immunological role of Acyl-CoA synthetase Long-Chain Family Member 4 in a Pan-cancer Analysis Front Genet 2022 13 812674 10.3389/fgene.2022.812674 35126480
Yu Y, Sun X, Chen F, Liu M. Genetic alteration, prognostic and immunological role of Acyl-CoA synthetase Long-Chain Family Member 4 in a Pan-cancer Analysis. Front Genet. 2022;13:812674.35126480 10.3389/fgene.2022.812674
113. Duan Y Gong K Xu S Zhang F Meng X Han J Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics Signal Transduct Target Ther 2022 7 1 265 10.1038/s41392-022-01125-5 35918332
Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7(1):265.35918332 10.1038/s41392-022-01125-5
114. Sharma B Agnihotri N Role of cholesterol homeostasis and its efflux pathways in cancer progression J Steroid Biochem Mol Biol 2019 191 105377 10.1016/j.jsbmb.2019.105377 31063804
Sharma B, Agnihotri N. Role of cholesterol homeostasis and its efflux pathways in cancer progression. J Steroid Biochem Mol Biol. 2019;191:105377.31063804 10.1016/j.jsbmb.2019.105377
115. Antmen E Yalaza ŞC Canacankatan N Aytan H Tuncel F Erden S Ertürk Efficacy of ABCA1 transporter proteins in patients with endometrial Cancer: an in Vitro Study Turk J Pharm Sci 2024 21 3 219 23 38994830
Antmen E, Yalaza ŞC, Canacankatan N, Aytan H, Tuncel F, Erden S, Ertürk. Efficacy of ABCA1 transporter proteins in patients with endometrial Cancer: an in Vitro Study. Turk J Pharm Sci. 2024;21(3):219–23.38994830
116. Wen Q Xie X Chen C Wen B Liu Y Zhou J Lin X Jin H Shi K Lipid reprogramming induced by the NNMT-ABCA1 axis enhanced membrane fluidity to promote endometrial cancer progression Aging 2023 15 21 11860 74 10.18632/aging.205142 37889548
Wen Q, Xie X, Chen C, Wen B, Liu Y, Zhou J, Lin X, Jin H, Shi K. Lipid reprogramming induced by the NNMT-ABCA1 axis enhanced membrane fluidity to promote endometrial cancer progression. Aging. 2023;15(21):11860–74.37889548 10.18632/aging.205142
117. Shimano H Sato R SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology Nat Rev Endocrinol 2017 13 12 710 30 10.1038/nrendo.2017.91 28849786
Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13(12):710–30.28849786 10.1038/nrendo.2017.91
118. DeBose-Boyd RA Ye J SREBPs in lipid metabolism, insulin signaling, and Beyond Trends Biochem Sci 2018 43 5 358 68 10.1016/j.tibs.2018.01.005 29500098
DeBose-Boyd RA, Ye J. SREBPs in lipid metabolism, insulin signaling, and Beyond. Trends Biochem Sci. 2018;43(5):358–68.29500098 10.1016/j.tibs.2018.01.005
119. Shao W Espenshade PJ Expanding roles for SREBP in metabolism Cell Metab 2012 16 4 414 9 10.1016/j.cmet.2012.09.002 23000402
Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab. 2012;16(4):414–9.23000402 10.1016/j.cmet.2012.09.002
120. Zhao Q Lin X Wang G Targeting SREBP-1-Mediated lipogenesis as potential strategies for Cancer Front Oncol 2022 12 952371 10.3389/fonc.2022.952371 35912181
Zhao Q, Lin X, Wang G. Targeting SREBP-1-Mediated lipogenesis as potential strategies for Cancer. Front Oncol. 2022;12:952371.35912181 10.3389/fonc.2022.952371
121. Xue L Qi H Zhang H Ding L Huang Q Zhao D Wu BJ Li X Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy Front Oncol 2020 10 1510 10.3389/fonc.2020.01510 32974183
Xue L, Qi H, Zhang H, Ding L, Huang Q, Zhao D, Wu BJ, Li X. Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy. Front Oncol. 2020;10:1510.32974183 10.3389/fonc.2020.01510
122. Shafiee MN Mongan N Seedhouse C Chapman C Deen S Abu J Atiomo W Sterol regulatory element binding protein-1 (SREBP1) gene expression is similarly increased in polycystic ovary syndrome and endometrial cancer Acta Obstet Gynecol Scand 2017 96 5 556 62 10.1111/aogs.13106 28176325
Shafiee MN, Mongan N, Seedhouse C, Chapman C, Deen S, Abu J, Atiomo W. Sterol regulatory element binding protein-1 (SREBP1) gene expression is similarly increased in polycystic ovary syndrome and endometrial cancer. Acta Obstet Gynecol Scand. 2017;96(5):556–62.28176325 10.1111/aogs.13106
123. Li W Tai Y Zhou J Gu W Bai Z Zhou T Zhong Z McCue PA Sang N Ji JY Kong B Jiang J Wang C Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis Cell Cycle 2012 11 12 2348 58 10.4161/cc.20811 22672904
Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, Zhong Z, McCue PA, Sang N, Ji JY, Kong B, Jiang J, Wang C. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 2012;11(12):2348–58.22672904 10.4161/cc.20811
124. Qiu CP Lv QT Dongol S Wang C Jiang J Single nucleotide polymorphism of SREBF-1 gene associated with an increased risk of endometrial cancer in Chinese women PLoS ONE 2014 9 3 e90491 10.1371/journal.pone.0090491 24614076
Qiu CP, Lv QT, Dongol S, Wang C, Jiang J. Single nucleotide polymorphism of SREBF-1 gene associated with an increased risk of endometrial cancer in Chinese women. PLoS ONE. 2014;9(3):e90491.24614076 10.1371/journal.pone.0090491
125. Lin CY Gustafsson J Targeting liver X receptors in cancer therapeutics Nat Rev Cancer 2015 15 4 216 24 10.1038/nrc3912 25786697
Lin CY, Gustafsson J. Targeting liver X receptors in cancer therapeutics. Nat Rev Cancer. 2015;15(4):216–24.25786697 10.1038/nrc3912
126. Repa JJ Liang G Ou J Bashmakov Y Lobaccaro JM Shimomura I Shan B Brown MS Goldstein JL Mangelsdorf DJ Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta Genes Dev 2000 14 22 2819 30 10.1101/gad.844900 11090130
Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14(22):2819–30.11090130 10.1101/gad.844900
127. Zhang X Liu J Su W Wu J Wang C Kong X Gustafsson J Ding J Ma X Guan Y Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism J Diabetes 2014 6 3 212 20 10.1111/1753-0407.12081 23945440
Zhang X, Liu J, Su W, Wu J, Wang C, Kong X, Gustafsson J, Ding J, Ma X, Guan Y. Liver X receptor activation increases hepatic fatty acid desaturation by the induction of SCD1 expression through an LXRα-SREBP1c-dependent mechanism. J Diabetes. 2014;6(3):212–20.23945440 10.1111/1753-0407.12081
128. Zelcer N Hong C Boyadjian R Tontonoz P LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor Science 2009 325 5936 100 4 10.1126/science.1168974 19520913
Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009;325(5936):100–4.19520913 10.1126/science.1168974
129. Wang B Tontonoz P Liver X receptors in lipid signalling and membrane homeostasis Nat Rev Endocrinol 2018 14 8 452 63 10.1038/s41574-018-0037-x 29904174
Wang B, Tontonoz P. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018;14(8):452–63.29904174 10.1038/s41574-018-0037-x
130. Fang F Li D Zhao L Li Y Zhang T Cui B Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro Onco Targets Ther 2019 12 685 97 10.2147/OTT.S180534 30705597
Fang F, Li D, Zhao L, Li Y, Zhang T, Cui B. Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro. Onco Targets Ther. 2019;12:685–97.30705597 10.2147/OTT.S180534
131. Abdalkareem Jasim S Kzar HH Haider Hamad M Ahmad I Al-Gazally ME Ziyadullaev S Sivaraman R Abed Jawad M Thaeer Hammid A Oudaha KH Karampoor S Mirzaei R The emerging role of 27-hydroxycholesterol in cancer development and progression: an update Int Immunopharmacol 2022 110 109074 10.1016/j.intimp.2022.109074 35978522
Abdalkareem Jasim S, Kzar HH, Haider Hamad M, Ahmad I, Al-Gazally ME, Ziyadullaev S, Sivaraman R, Abed Jawad M, Thaeer Hammid A, Oudaha KH, Karampoor S, Mirzaei R. The emerging role of 27-hydroxycholesterol in cancer development and progression: an update. Int Immunopharmacol. 2022;110:109074.35978522 10.1016/j.intimp.2022.109074
132. Gibson DA Collins F Cousins FL Esnal Zufiaurre A Saunders PTK The impact of 27-hydroxycholesterol on endometrial cancer proliferation Endocr Relat Cancer 2018 25 4 381 91 10.1530/ERC-17-0449 29371332
Gibson DA, Collins F, Cousins FL, Esnal Zufiaurre A, Saunders PTK. The impact of 27-hydroxycholesterol on endometrial cancer proliferation. Endocr Relat Cancer. 2018;25(4):381–91.29371332 10.1530/ERC-17-0449
133. Christofides A Konstantinidou E Jani C Boussiotis VA The role of peroxisome proliferator-activated receptors (PPAR) in immune responses Metabolism 2021 114 154338 10.1016/j.metabol.2020.154338 32791172
Christofides A, Konstantinidou E, Jani C, Boussiotis VA. The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism. 2021;114:154338.32791172 10.1016/j.metabol.2020.154338
134. Mirza AZ Althagafi II Shamshad H Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications Eur J Med Chem 2019 166 502 13 10.1016/j.ejmech.2019.01.067 30739829
Mirza AZ, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications. Eur J Med Chem. 2019;166:502–13.30739829 10.1016/j.ejmech.2019.01.067
135. Wagner N Wagner KD Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer Cells 2022 11 15 2432 10.3390/cells11152432 35954274
Wagner N, Wagner KD. Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer. Cells. 2022;11(15):2432.35954274 10.3390/cells11152432
136. Tong BJ Tan J Tajeda L Das SK Chapman JA DuBois RN Dey SK Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma Neoplasia 2000 2 6 483 90 10.1038/sj.neo.7900119 11228540
Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia. 2000;2(6):483–90.11228540 10.1038/sj.neo.7900119
137. Knapp P Chabowski A Błachnio-Zabielska A Jarząbek K Wołczyński S Altered peroxisome-proliferator activated receptors expression in human endometrial cancer PPAR Res 2012 2012 471524 10.1155/2012/471524 22448166
Knapp P, Chabowski A, Błachnio-Zabielska A, Jarząbek K, Wołczyński S. Altered peroxisome-proliferator activated receptors expression in human endometrial cancer. PPAR Res. 2012;2012:471524.22448166 10.1155/2012/471524
138. Zhang G Hou X Gao S Stimulation of peroxisome proliferator-activated receptor γ inhibits estrogen receptor α transcriptional activity in endometrial carcinoma cells Oncol Rep 2015 33 3 1227 34 10.3892/or.2015.3729 25592200
Zhang G, Hou X, Gao S. Stimulation of peroxisome proliferator-activated receptor γ inhibits estrogen receptor α transcriptional activity in endometrial carcinoma cells. Oncol Rep. 2015;33(3):1227–34.25592200 10.3892/or.2015.3729
139. Ota K Ito K Suzuki T Saito S Tamura M Hayashi S Okamura K Sasano H Yaegashi N Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma Clin Cancer Res 2006 12 14 Pt 1 4200 8 10.1158/1078-0432.CCR-05-1833 16857792
Ota K, Ito K, Suzuki T, Saito S, Tamura M, Hayashi S, Okamura K, Sasano H, Yaegashi N. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res. 2006;12(14 Pt 1):4200–8.16857792 10.1158/1078-0432.CCR-05-1833
140. Nickkho-Amiry M McVey R Holland C Peroxisome proliferator-activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma Mol Cancer Res 2012 10 3 441 53 10.1158/1541-7786.MCR-11-0233 22205725
Nickkho-Amiry M, McVey R, Holland C. Peroxisome proliferator-activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma. Mol Cancer Res. 2012;10(3):441–53.22205725 10.1158/1541-7786.MCR-11-0233
141. Lu YU Miyamoto T Takeuchi H Tsunoda F Tanaka N Shiozawa T PPARα activator irbesartan suppresses the proliferation of endometrial carcinoma cells via SREBP1 and ARID1A Oncol Res 2023 31 3 239 53 10.32604/or.2023.026067 37305395
Lu YU, Miyamoto T, Takeuchi H, Tsunoda F, Tanaka N, Shiozawa T. PPARα activator irbesartan suppresses the proliferation of endometrial carcinoma cells via SREBP1 and ARID1A. Oncol Res. 2023;31(3):239–53.37305395 10.32604/or.2023.026067
142. Ma JJ Monsivais D Dyson MT Coon JS Malpani S Ono M Zhao H Xin H Pavone ME Kim JJ Chakravarti D Bulun SE Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival Horm Cancer 2013 4 6 358 70 10.1007/s12672-013-0157-7 23943160
Ma JJ, Monsivais D, Dyson MT, Coon JS, Malpani S, Ono M, Zhao H, Xin H, Pavone ME, Kim JJ, Chakravarti D, Bulun SE. Ligand-activated peroxisome proliferator-activated receptor β/δ modulates human endometrial cancer cell survival. Horm Cancer. 2013;4(6):358–70.23943160 10.1007/s12672-013-0157-7
143. Schcolnik-Cabrera A Chávez-Blanco A Domínguez-Gómez G Taja-Chayeb L Morales-Barcenas R Trejo-Becerril C Perez-Cardenas E Gonzalez-Fierro A Dueñas-González, Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy Expert Opin Investig Drugs 2018 27 5 475 89 10.1080/13543784.2018.1471132 29723075
Schcolnik-Cabrera A, Chávez-Blanco A, Domínguez-Gómez G, Taja-Chayeb L, Morales-Barcenas R, Trejo-Becerril C, Perez-Cardenas E, Gonzalez-Fierro A. Dueñas-González, Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy. Expert Opin Investig Drugs. 2018;27(5):475–89.29723075 10.1080/13543784.2018.1471132
144. Wysham WZ Roque DR Han J Zhang L Guo H Gehrig PA Zhou C Bae-Jump VL Effects of fatty acid synthase inhibition by Orlistat on Proliferation of Endometrial Cancer Cell lines Target Oncol 2016 11 6 763 9 10.1007/s11523-016-0442-9 27188391
Wysham WZ, Roque DR, Han J, Zhang L, Guo H, Gehrig PA, Zhou C, Bae-Jump VL. Effects of fatty acid synthase inhibition by Orlistat on Proliferation of Endometrial Cancer Cell lines. Target Oncol. 2016;11(6):763–9.27188391 10.1007/s11523-016-0442-9
145. Falchook G Infante J Arkenau HT Patel MR Dean E Borazanci E Brenner A Cook N Lopez J Pant S Frankel A Schmid P Moore K McCulloch W Grimmer K O’Farrell M Kemble G Burris H First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors EClinicalMedicine 2021 34 100797 10.1016/j.eclinm.2021.100797 33870151
Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, Brenner A, Cook N, Lopez J, Pant S, Frankel A, Schmid P, Moore K, McCulloch W, Grimmer K, O’Farrell M, Kemble G, Burris H. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797.33870151 10.1016/j.eclinm.2021.100797
146. Sun Q Xing X Wang H Wan K Fan R Liu C Wang Y Wu W Wang Y Wang R SCD1 is the critical signaling hub to mediate metabolic diseases: mechanism and the development of its inhibitors Biomed Pharmacother 2024 170 115586 10.1016/j.biopha.2023.115586 38042113
Sun Q, Xing X, Wang H, Wan K, Fan R, Liu C, Wang Y, Wu W, Wang Y, Wang R. SCD1 is the critical signaling hub to mediate metabolic diseases: mechanism and the development of its inhibitors. Biomed Pharmacother. 2024;170:115586.38042113 10.1016/j.biopha.2023.115586
147. Wang KH Liu CH Ding DC Statins as Repurposed Drugs in Gynecological Cancer: A Review Int J Mol Sci 2022 23 22 13937 10.3390/ijms232213937 36430409
Wang KH, Liu CH, Ding DC. Statins as Repurposed Drugs in Gynecological Cancer: A Review. Int J Mol Sci. 2022;23(22):13937.36430409 10.3390/ijms232213937
148. Jiang W Hu JW He XR Jin WL He XY Statins: a repurposed drug to fight cancer J Exp Clin Cancer Res 2021 40 1 241 10.1186/s13046-021-02041-2 34303383
Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241.34303383 10.1186/s13046-021-02041-2
149. Schointuch MN Gilliam TP Stine JE Han X Zhou C Gehrig PA Kim K Bae-Jump VL Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer Gynecol Oncol 2014 134 2 346 55 10.1016/j.ygyno.2014.05.015 24880141
Schointuch MN, Gilliam TP, Stine JE, Han X, Zhou C, Gehrig PA, Kim K, Bae-Jump VL. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecol Oncol. 2014;134(2):346–55.24880141 10.1016/j.ygyno.2014.05.015
150. Zhou D Wu Q Qiu H Li M Ji Y Simvastatin inhibits endometrial cancer malignant behaviors by suppressing RAS/Mitogen-Activated Protein Kinase (MAPK) pathway-mediated Reactive Oxygen Species (ROS) and ferroptosis Evid Based Complement Alternat Med 2022 2022 6177477 10.1155/2022/6177477 36276874
Zhou D, Wu Q, Qiu H, Li M, Ji Y. Simvastatin inhibits endometrial cancer malignant behaviors by suppressing RAS/Mitogen-Activated Protein Kinase (MAPK) pathway-mediated Reactive Oxygen Species (ROS) and ferroptosis. Evid Based Complement Alternat Med. 2022;2022:6177477.36276874 10.1155/2022/6177477
151. Kim JS Turbov J Rosales R Thaete LG Rodriguez GC Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth Gynecol Oncol 2019 154 2 432 40 10.1016/j.ygyno.2019.05.022 31178149
Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC. Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth. Gynecol Oncol. 2019;154(2):432–40.31178149 10.1016/j.ygyno.2019.05.022
152. Cai Y Zhao F Fluvastatin suppresses the proliferation, invasion, and migration and promotes the apoptosis of endometrial cancer cells by upregulating Sirtuin 6 (SIRT6) Bioengineered 2021 12 2 12509 20 10.1080/21655979.2021.2009415 34927546
Cai Y, Zhao F. Fluvastatin suppresses the proliferation, invasion, and migration and promotes the apoptosis of endometrial cancer cells by upregulating Sirtuin 6 (SIRT6). Bioengineered. 2021;12(2):12509–20.34927546 10.1080/21655979.2021.2009415
153. Xu R Song J Ruze R Chen Y Yin X Wang C Zhao Y SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway Cell Death Dis 2023 14 8 497 10.1038/s41419-023-05987-7 37542052
Xu R, Song J, Ruze R, Chen Y, Yin X, Wang C, Zhao Y. SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway. Cell Death Dis. 2023;14(8):497.37542052 10.1038/s41419-023-05987-7
154. Sun H Li L Li W Yang F Zhang Z Liu Z Du W p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth EMBO Rep 2021 22 10 e52537 10.15252/embr.202152537 34459531
Sun H, Li L, Li W, Yang F, Zhang Z, Liu Z, Du W. p53 transcriptionally regulates SQLE to repress cholesterol synthesis and tumor growth. EMBO Rep. 2021;22(10):e52537.34459531 10.15252/embr.202152537
155. Du Y Rokavec M Hermeking H Squalene epoxidase/SQLE is a candidate target for treatment of colorectal cancers with p53 mutation and elevated c-MYC expression Int J Biol Sci 2023 19 13 4103 22 10.7150/ijbs.85724 37705742
Du Y, Rokavec M, Hermeking H. Squalene epoxidase/SQLE is a candidate target for treatment of colorectal cancers with p53 mutation and elevated c-MYC expression. Int J Biol Sci. 2023;19(13):4103–22.37705742 10.7150/ijbs.85724
156. Gao S Shi Z Li X Li W Wang Y Liu Z Jiang J Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma Oncol Rep 2018 39 4 1919 29 29436682
Gao S, Shi Z, Li X, Li W, Wang Y, Liu Z, Jiang J. Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma. Oncol Rep. 2018;39(4):1919–29.29436682
157. Yao L Chen S Li W Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism Arch Biochem Biophys 2020 684 108327 10.1016/j.abb.2020.108327 32142890
Yao L, Chen S, Li W. Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism. Arch Biochem Biophys. 2020;684:108327.32142890 10.1016/j.abb.2020.108327
158. Wang Q Hu R Li W Tai Y Gu W Das BC Yang F Ji J Wang C Zhou J BF175 inhibits endometrial carcinoma through SREBP-regulated metabolic pathways in vitro Mol Cell Endocrinol 2021 523 111135 10.1016/j.mce.2020.111135 33359761
Wang Q, Hu R, Li W, Tai Y, Gu W, Das BC, Yang F, Ji J, Wang C, Zhou J. BF175 inhibits endometrial carcinoma through SREBP-regulated metabolic pathways in vitro. Mol Cell Endocrinol. 2021;523:111135.33359761 10.1016/j.mce.2020.111135
159. Shi Z Zhou Q Gao S Li W Li X Liu Z Jin P Jiang J Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation Life Sci 2019 217 70 80 10.1016/j.lfs.2018.11.037 30452972
Shi Z, Zhou Q, Gao S, Li W, Li X, Liu Z, Jin P, Jiang J. Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation. Life Sci. 2019;217:70–80.30452972 10.1016/j.lfs.2018.11.037
160. Sun J Zheng Z Chen Q Pan Y Quan M Dai Y Fenofibrate potentiates chemosensitivity to human breast cancer cells by modulating apoptosis via AKT/NF-κB pathway Onco Targets Ther 2019 12 773 83 10.2147/OTT.S191239 30774365
Sun J, Zheng Z, Chen Q, Pan Y, Quan M, Dai Y. Fenofibrate potentiates chemosensitivity to human breast cancer cells by modulating apoptosis via AKT/NF-κB pathway. Onco Targets Ther. 2019;12:773–83.30774365 10.2147/OTT.S191239
161. Luty M Piwowarczyk K Łabędź-Masłowska A Wróbel T Szczygieł M Catapano J Drabik G Ryszawy D Kędracka-Krok S Madeja Z Siedlar M Elas M Czyż J Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel Cancers (Basel) 2019 11 1 77 10.3390/cancers11010077 30641904
Luty M, Piwowarczyk K, Łabędź-Masłowska A, Wróbel T, Szczygieł M, Catapano J, Drabik G, Ryszawy D, Kędracka-Krok S, Madeja Z, Siedlar M, Elas M, Czyż J. Fenofibrate Augments the Sensitivity of Drug-Resistant Prostate Cancer Cells to Docetaxel. Cancers (Basel). 2019;11(1):77.30641904 10.3390/cancers11010077
162. Wang MS Han QS Jia ZR Chen CS Qiao C Liu QQ Zhang YM Wang KW Wang J Xiao K Ding XS PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway Acta Pharmacol Sin 2022 43 1 167 76 10.1038/s41401-021-00638-z 33772142
Wang MS, Han QS, Jia ZR, Chen CS, Qiao C, Liu QQ, Zhang YM, Wang KW, Wang J, Xiao K, Ding XS. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway. Acta Pharmacol Sin. 2022;43(1):167–76.33772142 10.1038/s41401-021-00638-z
163. Holland CM Saidi SA Evans AL Sharkey AM Latimer JA Crawford RA Charnock-Jones DS Print CG Smith SK Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets Mol Cancer Ther 2004 3 8 993 1001 10.1158/1535-7163.993.3.8 15299082
Holland CM, Saidi SA, Evans AL, Sharkey AM, Latimer JA, Crawford RA, Charnock-Jones DS, Print CG, Smith SK. Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets. Mol Cancer Ther. 2004;3(8):993–1001.15299082 10.1158/1535-7163.993.3.8
164. Saidi SA Holland CM Charnock-Jones DS Smith SK In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer Mol Cancer 2006 5 13 10.1186/1476-4598-5-13 16569247
Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006;5:13.16569247 10.1186/1476-4598-5-13
165. Kumari GK Kiran A Krishnamurthy PT Preliminary evaluation on the beneficial effects of pioglitazone in the treatment of endometrial cancer Med Oncol 2021 38 6 71 10.1007/s12032-021-01521-x 34008039
Kumari GK, Kiran A, Krishnamurthy PT. Preliminary evaluation on the beneficial effects of pioglitazone in the treatment of endometrial cancer. Med Oncol. 2021;38(6):71.34008039 10.1007/s12032-021-01521-x
